KR20060033345A - Herbextract for removing harmful elements caused by smoking and manufacturing method of the same - Google Patents
Herbextract for removing harmful elements caused by smoking and manufacturing method of the same Download PDFInfo
- Publication number
- KR20060033345A KR20060033345A KR1020040082405A KR20040082405A KR20060033345A KR 20060033345 A KR20060033345 A KR 20060033345A KR 1020040082405 A KR1020040082405 A KR 1020040082405A KR 20040082405 A KR20040082405 A KR 20040082405A KR 20060033345 A KR20060033345 A KR 20060033345A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- smoking
- herbal
- solvent
- Prior art date
Links
- 230000000391 smoking effect Effects 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 239000012676 herbal extract Substances 0.000 claims abstract description 81
- 239000000284 extract Substances 0.000 claims abstract description 54
- 239000002904 solvent Substances 0.000 claims abstract description 38
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 31
- 241001116389 Aloe Species 0.000 claims abstract description 24
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 24
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 24
- 229940010454 licorice Drugs 0.000 claims abstract description 24
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 23
- 238000000605 extraction Methods 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 235000005881 Calendula officinalis Nutrition 0.000 claims abstract description 15
- 238000001704 evaporation Methods 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 239000011343 solid material Substances 0.000 claims abstract description 5
- 240000001548 Camellia japonica Species 0.000 claims abstract description 4
- 235000018597 common camellia Nutrition 0.000 claims abstract description 4
- 240000000785 Tagetes erecta Species 0.000 claims abstract 5
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 244000269722 Thea sinensis Species 0.000 claims description 32
- 235000009569 green tea Nutrition 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000004615 ingredient Substances 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 5
- 235000021307 Triticum Nutrition 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 235000008434 ginseng Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000003021 water soluble solvent Substances 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 4
- 241000209140 Triticum Species 0.000 claims 2
- 244000248416 Fagopyrum cymosum Species 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 235000012041 food component Nutrition 0.000 claims 1
- 239000005417 food ingredient Substances 0.000 claims 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract description 45
- 229960002715 nicotine Drugs 0.000 abstract description 45
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract description 45
- 210000004369 blood Anatomy 0.000 abstract description 32
- 239000008280 blood Substances 0.000 abstract description 32
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 27
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 10
- 235000009024 Ceanothus sanguineus Nutrition 0.000 abstract description 5
- 240000003553 Leptospermum scoparium Species 0.000 abstract description 5
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 5
- 244000061176 Nicotiana tabacum Species 0.000 abstract description 5
- 240000008620 Fagopyrum esculentum Species 0.000 abstract description 4
- 235000009419 Fagopyrum esculentum Nutrition 0.000 abstract description 4
- 239000000052 vinegar Substances 0.000 abstract description 4
- 235000021419 vinegar Nutrition 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 241001122767 Theaceae Species 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 238000012360 testing method Methods 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 239000003814 drug Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 23
- 235000019441 ethanol Nutrition 0.000 description 21
- 238000011084 recovery Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 150000004676 glycans Chemical class 0.000 description 18
- 229920001282 polysaccharide Polymers 0.000 description 18
- 239000005017 polysaccharide Substances 0.000 description 18
- 230000003078 antioxidant effect Effects 0.000 description 17
- 239000003963 antioxidant agent Substances 0.000 description 16
- 235000006708 antioxidants Nutrition 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 16
- 239000002253 acid Substances 0.000 description 14
- 230000009471 action Effects 0.000 description 14
- 241000208125 Nicotiana Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 239000004378 Glycyrrhizin Substances 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 229930003935 flavonoid Natural products 0.000 description 12
- 150000002215 flavonoids Chemical class 0.000 description 12
- 235000017173 flavonoids Nutrition 0.000 description 12
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 12
- 229960004949 glycyrrhizic acid Drugs 0.000 description 12
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 12
- 235000019410 glycyrrhizin Nutrition 0.000 description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000779 smoke Substances 0.000 description 12
- 240000001432 Calendula officinalis Species 0.000 description 11
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 11
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 229910002091 carbon monoxide Inorganic materials 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 235000018553 tannin Nutrition 0.000 description 10
- 239000001648 tannin Substances 0.000 description 10
- 229920001864 tannin Polymers 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 229930182470 glycoside Natural products 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 235000013616 tea Nutrition 0.000 description 9
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 8
- 241001570521 Lonicera periclymenum Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- -1 bovine Chemical class 0.000 description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
- 230000029142 excretion Effects 0.000 description 8
- 150000002338 glycosides Chemical class 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 206010036790 Productive cough Diseases 0.000 description 7
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 229940097043 glucuronic acid Drugs 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 210000003802 sputum Anatomy 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- 235000017443 Hedysarum boreale Nutrition 0.000 description 6
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 244000010922 Plantago major Species 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 5
- 150000001746 carotenes Chemical class 0.000 description 5
- 235000005473 carotenes Nutrition 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 4
- 229940076810 beta sitosterol Drugs 0.000 description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 4
- 229960001948 caffeine Drugs 0.000 description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 229960003720 enoxolone Drugs 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 229940051810 licorice root extract Drugs 0.000 description 4
- 235000020725 licorice root extract Nutrition 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 4
- 229950005143 sitosterol Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000003805 Musa ABB Group Nutrition 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 235000015266 Plantago major Nutrition 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- 244000098338 Triticum aestivum Species 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 239000012159 carrier gas Substances 0.000 description 3
- 238000002485 combustion reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 201000004647 tinea pedis Diseases 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- NIZFPXZQERMCLE-KVFWHIKKSA-N (e)-1-[4-[(2s,3r,4s,5s,6r)-3-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O[C@H]1[C@@H]([C@@](O)(CO)CO1)O)O)CO)C(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 NIZFPXZQERMCLE-KVFWHIKKSA-N 0.000 description 2
- QUNWUDVFRNGTCO-UHFFFAOYSA-N 1,7-dimethylxanthine Chemical compound N1C(=O)N(C)C(=O)C2=C1N=CN2C QUNWUDVFRNGTCO-UHFFFAOYSA-N 0.000 description 2
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 2
- IRJNJBIOUYJBHG-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.CN1CCCC1C1=CC=CN=C1 IRJNJBIOUYJBHG-UHFFFAOYSA-N 0.000 description 2
- XLYLQUQHYUOPIW-UHFFFAOYSA-N 3-oxo-Tetradecanal Chemical compound CCCCCCCCCCCC(=O)CC=O XLYLQUQHYUOPIW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 244000242092 Aloe saponaria Species 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241001137251 Corvidae Species 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoylacetaldehyde Natural products CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241001420836 Ophthalmitis Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- BWPGKXYWPBQBPV-MWQJAWBESA-N Theasaponin Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)CO1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(C[C@H]14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BWPGKXYWPBQBPV-MWQJAWBESA-N 0.000 description 2
- BWPGKXYWPBQBPV-ZOADXXHESA-N Theasaponin Natural products O=C(O[C@@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@@H]7[C@H](O[C@@H]8[C@@H](O)[C@H](O)[C@H](O)CO8)[C@H](O)[C@@H](O)CO7)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C BWPGKXYWPBQBPV-ZOADXXHESA-N 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000893966 Trichophyton verrucosum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960003654 desoxycortone Drugs 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- HFJRKMMYBMWEAD-UHFFFAOYSA-N dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- VMMVZVPAYFZNBM-CMDYPFMGSA-N isoliquiritin apioside Natural products O=C(/C=C/c1ccc(O[C@H]2[C@@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)cc1)c1c(O)cc(O)cc1 VMMVZVPAYFZNBM-CMDYPFMGSA-N 0.000 description 2
- MYXNWGACZJSMBT-VJXVFPJBSA-N isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O MYXNWGACZJSMBT-VJXVFPJBSA-N 0.000 description 2
- OYJCWTROZCNWAA-UHFFFAOYSA-N isovitexin Natural products OCC1OC(C(O)C(O)C1O)c2c(O)cc3CC(=CC(=O)c3c2O)c4ccc(O)cc4 OYJCWTROZCNWAA-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020094 liqueur Nutrition 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 2
- 235000009498 luteolin Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229940005121 nicotine 4 mg Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 208000010403 panophthalmitis Diseases 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 229920003175 pectinic acid Polymers 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940026510 theanine Drugs 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- IOPDFSGGBHSXSV-ZPWDLUOLSA-N (3s,4ar,6ar,6ar,6br,8s,8as,12s,12as,14ar,14br)-4,4,6a,6b,8a,12,14b-heptamethyl-11-methylidene-1,2,3,4a,5,6,6a,7,8,9,10,12,12a,13,14,14a-hexadecahydropicene-3,8-diol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)[C@@H](O)C[C@]21C IOPDFSGGBHSXSV-ZPWDLUOLSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- DZFBLMREUFPTIY-UHFFFAOYSA-N 1-chlorobutan-1-ol;hydrate Chemical compound O.CCCC(O)Cl DZFBLMREUFPTIY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 240000007474 Aloe arborescens Species 0.000 description 1
- 244000093345 Aloe arborescens var. natalensis Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000009447 Cardiac Edema Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241001609679 Cuscuta japonica Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241001668545 Pascopyrum Species 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001499733 Plantago asiatica Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- MBWUSSKCCUMJHO-ZGXDEBHDSA-N Solamargine Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O MBWUSSKCCUMJHO-ZGXDEBHDSA-N 0.000 description 1
- MBWUSSKCCUMJHO-DVDUUUGDSA-N Solamargine Natural products O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@@]6(O[C@H]5C4)NC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](C)O1 MBWUSSKCCUMJHO-DVDUUUGDSA-N 0.000 description 1
- 235000002594 Solanum nigrum Nutrition 0.000 description 1
- 244000061457 Solanum nigrum Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- VSJGJMKGNMDJCI-ZASXJUAOSA-N Sweroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](CCOC2=O)C2=CO1 VSJGJMKGNMDJCI-ZASXJUAOSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000736851 Tagetes Species 0.000 description 1
- 235000012308 Tagetes Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000004381 Uterine cervical erosion Diseases 0.000 description 1
- 206010065811 Uterine fistula Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229960004784 allergens Drugs 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- RXVGBQCEAQZMLW-UHFFFAOYSA-N alpha-solanine Natural products CC1CCC2C(C)C3C(CC4C5CC=C6CC(CCC6(C)C5CCC34C)OC7OC(CO)C(O)C(OC8OC(CO)C(O)C(O)C8O)C7OC9OC(CO)C(O)C(O)C9O)N2C1 RXVGBQCEAQZMLW-UHFFFAOYSA-N 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-N angelic acid Chemical compound C\C=C(\C)C(O)=O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- IOPDFSGGBHSXSV-UHFFFAOYSA-N arnidiol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(=C)CCC3(C)C(O)CC21C IOPDFSGGBHSXSV-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- BLRFKPWRSOZROE-UHFFFAOYSA-N beta-Solamargin Natural products CC1CCC2(NC1)OC3CC4C5CC=C6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(COC8OC(C)C(OC9OC(C)C(O)C(O)C9O)C(O)C8O)C(O)C(O)C7O BLRFKPWRSOZROE-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229930008677 glyco alkaloid Natural products 0.000 description 1
- AIHKAQUFJMNPAR-UHFFFAOYSA-N glyphoside Chemical compound O1C(CO)C(O)C(O)C(OC(=O)C)C1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O AIHKAQUFJMNPAR-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000011874 heated mixture Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- AMBQHHVBBHTQBF-DLXIZZNVSA-N methyl 6-hydroxy-7-methyl-1-[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate Chemical compound C12C(C)C(O)CC2C(C(=O)OC)=COC1O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O AMBQHHVBBHTQBF-DLXIZZNVSA-N 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000021188 national dish Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 125000002072 seryl group Chemical group 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- BIMWFUACEQGSPS-UHFFFAOYSA-N solamargin Natural products CC1CCC2(NC1)OC3CC4C5CC=C6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(COC8OC(C)C(O)C(O)C8O)C(O)C(O)C7OC9OC(C)C(O)C(O)C9O BIMWFUACEQGSPS-UHFFFAOYSA-N 0.000 description 1
- 229940031352 solanine Drugs 0.000 description 1
- ZGVSETXHNHBTRK-OTYSSXIJSA-N solanine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5N6C[C@@H](C)CC[C@@H]6[C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZGVSETXHNHBTRK-OTYSSXIJSA-N 0.000 description 1
- KWVISVAMQJWJSZ-VKROHFNGSA-N solasodine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CN1 KWVISVAMQJWJSZ-VKROHFNGSA-N 0.000 description 1
- JXWLYDNHVXFBJA-UHFFFAOYSA-N solasodine Natural products CC1CCC2(NC1)NC3CC4C5CC=C6CC(O)CCC6(C)C5CCC4(C)C3C2C JXWLYDNHVXFBJA-UHFFFAOYSA-N 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229930003352 steroid alkaloid Natural products 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- VSJGJMKGNMDJCI-QXSNVGMTSA-N sweroside Natural products OC[C@H]1O[C@H](O[C@@H]2OC=C3[C@@H](CCOC3=O)[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O VSJGJMKGNMDJCI-QXSNVGMTSA-N 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- BYGOPQKDHGXNCD-UHFFFAOYSA-N tripotassium;iron(3+);hexacyanide Chemical compound [K+].[K+].[K+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] BYGOPQKDHGXNCD-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 흡연으로 인한 니코틴 및 타르 성분의 제거 및 인체내의 면연력 강화를 위한 생약추출물 및 이의 제조방법에 관하여 개시한다. 생약추출물의 제조방법은 알로에, 금잔화, 까마중, 삼칠, 차나무, 약모밀, 새삼덩굴, 인동덩굴, 감초 및 차전초를 각각 건조하여 건조물을 형성하는 제1단계와, 상기 제1단계의 각 건조물에 용매를 넣고 가열하여 건조물의 성분이 용매에 추출된 추출용액을 형성하는 제2단계와, 상기 제2단계의 추출용액을 여과하여 고형물질을 제거하는 제3단계와, 상기 제3단계의 여과된 추출용액에 함유된 용매성분을 증발시켜 각각의 추출물을 얻는 제4단계 및 상기 제4단계의 추출물을 소정의 비율로 혼합하여 혼합추출물을 제공하는 제5단계를 포함한다.The present invention relates to a herbal extract for the removal of nicotine and tar components due to smoking and to strengthen the softening in the human body and a method for producing the same. The method of manufacturing the herbal extracts comprises a first step of drying the aloe, marigold, camellia, samchil, tea tree, buckwheat, bird vine, honeysuckle, licorice and tea vinegar, respectively, to form a dry matter, and a solvent in each dry matter of the first step. A second step of forming an extraction solution in which the dried component is extracted in a solvent by heating the mixture, a third step of removing the solid material by filtering the extraction solution of the second step, and the filtered extraction solution of the third step And a fifth step of obtaining each extract by evaporating the solvent component contained therein and a fifth step of mixing the extract of the fourth step in a predetermined ratio to provide a mixed extract.
본 발명에 따른 생약추출물은 담배 흡연으로 인해 인체내의 축적된 타르 및 혈액중의 니코틴 양을 저하시키는데 효과가 있다. 또한 본 발명의 생약추출물은 기능성 식품에 첨가하여 간편하게 복용할 수 있을 뿐만 아니라 다양한 형태의 제제로 제조하여 공급할 수 있는 이점을 제공한다.The herbal extract according to the present invention is effective in reducing the amount of tar and nicotine in the blood accumulated in the human body due to tobacco smoking. In addition, the herbal extract of the present invention provides an advantage that can be easily added to the functional food to be prepared and supplied in various forms of preparation.
생약추출물, 니코틴, 타르, 담배.Herbal extracts, nicotine, tar, tobacco.
Description
본 발명은 흡연으로 인한 유해성분 제거용 생약추출물 및 이의 제조방법에 관한 것이다. 더 상세하게는 담배 흡연으로 인한 니코틴 및 타르 성분의 제거를 위한 생약추출물 및 이의 제조방법에 관한 것이다.The present invention relates to a herbal extract for removing harmful components due to smoking and a method of manufacturing the same. More specifically, the present invention relates to a herbal extract for the removal of nicotine and tar components due to tobacco smoking and a method of manufacturing the same.
인체의 건강에 피해를 주는 물질 중에 담배가 차지하는 비중은 커지고 있는 추세이다. 흡연과 질병발생과의 관련성에 대한 연구는 1900년대 중반 이후 집중적으로 연구되기 시작했으며, 흡연으로 인한 폐암을 비롯한 각종 질병의 발생 증가와 다른 건강장애에 대한 증거가 지속적으로 쌓이고 있다. 실제로 담배연기는 주류연(mainstream smoke)과 부류연(sidestream smoke)으로 구성되어 있으며, 주류연은 흡연자가 들이마신 후 내품는 연기이고, 부류연은 타고 있는 담배 끝에서 나오는 생담배연기를 말한다. Tobacco accounts for an increasing proportion of substances that harm human health. The research on the relationship between smoking and disease occurrence has been intensively studied since the mid 1900s, and there is a continuous evidence of increasing the incidence of various diseases including lung cancer caused by smoking and other health disorders. In fact, tobacco smoke consists of mainstream smoke and sidestream smoke, which is smoke after smoker breathes, and smoke refers to live tobacco smoke from the end of a burning cigarette.
담배연기의 성분 분석 결과 약 4,000 여종의 성분이 확인 되었다. 약 4,000 여종의 성분이 주류연 총중량의 약 95%이상을 차지하고 있으며, 나머지 수천 종의 성분은 극히 미량으로 존재한다. 담배연기는 담배의 불완전 연소로 발생하며 완전연소가 되면 물과 이산화탄소가 발생한다. 불완전연소는 일부 담배잎 성분의 불완전 연소성, 불충분한 산소공급, 이외에도 담배가 탈 때 증류, 승화, 열분해, 열 합성, 휘발성의 과정을 거쳐 일어난다.As a result of the component analysis of tobacco smoke, about 4,000 species were identified. About 4,000 species account for more than 95% of the total weight of the mainstream smoke, while thousands of other components are present in extremely small amounts. Tobacco smoke is caused by incomplete combustion of tobacco, and when it is completely burned, water and carbon dioxide are generated. Incomplete combustion occurs through the incomplete combustibility of some tobacco leaf components, insufficient oxygen supply, as well as distillation, sublimation, pyrolysis, thermal synthesis, and volatility during tobacco burning.
담배연기는 기체에 액체 또는 미세한 입자가 섞여 있는 혼합체인 연무질(aerosol)로서, 캠브리지 유리섬유필터(Cambridge glass fiber filter;입자의 직경이 0.1㎛ 보다 큰 입자를 99% 이상 걸러낼 수 효율을 가진 필터)를 통과한 물질을 가스 또는 증기 성분이라 한다. 상기 가스 또는 증기 성분은 질소(59%), 산소(13.4%), 이산화탄소(13.5%), 일산화탄소(3.2%) 등으로 이루어져 있으며, 기관지 섬모 작용에 대해 독성을 나타내는 알데히드, 케톤, 알코올, 에스테르 등과 같은 저 분자량을 갖는 휘발성 성분이 포함된다. Tobacco smoke is an aerosol that is a mixture of liquid or fine particles in a gas.A Cambridge glass fiber filter is a filter that can filter 99% or more of particles larger than 0.1 µm in diameter. Substances passed through) are called gas or vapor components. The gas or vapor component is made up of nitrogen (59%), oxygen (13.4%), carbon dioxide (13.5%), carbon monoxide (3.2%), and the like, aldehydes, ketones, alcohols, esters, etc., which are toxic to bronchial cilia. Volatile components having the same low molecular weight are included.
또한 유리섬유필터(cambridge glass fiber filter)에 의해 걸러진 물질을 입자상 물질(Particulates phase components)이라 하고 담배연기의 약 8%이고, 타르를 포함한 적어도 38개의 알려진 발암물질과 발암가능성 물질 및 니코틴이 있으며, 기타의 무기 및 유기화학 물질을 포함하고 있다. The material filtered by the camber glass fiber filter is also called Particulates phase components, which is about 8% of tobacco smoke, and there are at least 38 known carcinogens, including carcinogens, and carcinogens and nicotine, Other inorganic and organic chemicals are included.
최근의 연구에 의하면 21세기에 들어서도 담배는 여전히 인류의 건강에 가장 큰 피해를 주는 위험요인으로 남을 것으로 예상되지만, 그럼에도 불구하고 담배 애호가는 끽연의 습관을 끊는다는 일은 쉬운 일이 아니며, 또 끽연을 계속하면 담배연기로 인한 체내에 니코틴과 타르성분 등이 축적되는 문제점이 있다.Recent research suggests that in the 21st century, tobacco is still a major risk factor for human health, but nevertheless, it is not easy for tobacco lovers to quit smoking habits. There is a problem that nicotine and tar components accumulate in the body due to tobacco smoke.
본 발명은 상기와 같은 문제점을 해결하기 위한 것으로, 흡연으로 인해 인체의 축적된 니코틴과 타르 성분을 제거할 수 있는 생약추출물 및 이의 제조방법을 제공함에 그 목적이 있다. The present invention has been made to solve the above problems, and an object of the present invention is to provide a herbal extract that can remove the accumulated nicotine and tar components of the human body due to smoking and a method of manufacturing the same.
본 발명의 또다른 목적은 흡연으로 인한 유해성분은 제거할 수 있는 생약추출물을 식품화하여 기능성 식품을 제공할 수 있는 생약추출물 및 이의 제조방법을 제공하는 것이다.Still another object of the present invention is to provide a herbal extract and a method for preparing the same, which can provide a functional food product by extracting a herbal extract that can remove harmful components caused by smoking.
상기의 목적을 달성하기 위한 본 발명에 따른 흡연으로 인한 유해성분 제거용 생약추출물은 알로에 0.5~10 중량%, 금잔화 5~40 중량%, 까마중 5~20 중량%, 삼칠 0.5~10 중량%, 녹차엽 5~20 중량%, 차전초 5~40 중량%, 약모밀 5~40 중량%, 새삼덩굴 5~20 중량%, 인동덩굴 5~30 중량% 및 감초 0.5~10 중량%를 포함한다.Herbal extracts for removing harmful components due to smoking according to the present invention for achieving the above object is 0.5 to 10% by weight, marigold 5 to 40% by weight, 5 to 20% by weight in black, 0.5 to 10% by weight, green tea 5 to 20% by weight of leaves, 5 to 40% by weight of chajeoncho, 5 to 40% by weight of weak buckwheat, 5 to 20% by weight of bird vines, 5 to 30% by weight of honeysuckle and 0.5 to 10% by weight of licorice.
상기의 목적을 달성하기 위한 본 발명에 따른 흡연으로 인한 유해성분 제거용 생약추출물의 제조방법은 알로에, 금잔화, 까마중, 삼칠, 녹차엽, 약모밀, 새삼덩굴, 인동덩굴, 감초 및 차전초를 각각 건조하여 건조물을 형성하는 제1단계와, 상기 제1단계의 각 건조물에 용매를 넣고 가열하여 건조물의 성분이 용매에 추출된 추출용액을 형성하는 제2단계와, 상기 제2단계의 추출용액을 여과하여 고형물질을 제거하는 제3단계와, 상기 제3단계의 여과된 추출용액에 함유된 용매성분을 증발시켜 각각의 추출물을 얻는 제4단계 및 상기 제4단계의 추출물을 소정의 비율로 혼합하여 혼합추출물을 제공하는 제5단계를 포함한다.According to the present invention, a method of preparing a herbal extract for removing harmful ingredients due to smoking according to the present invention comprises drying aloe, marigold, black yam, samchil, green tea leaf, weak wheat, bird vine, honeysuckle, licorice and tea vinegar, respectively. A first step of forming a dry matter, a second step of forming an extraction solution in which the components of the dry matter are extracted in a solvent by adding a solvent to each of the dry matters of the first step, and filtering the extracting solution of the second step The third step of removing the solid material and the fourth step of obtaining each extract by evaporating the solvent component contained in the filtered extract solution of the third step and the extract of the fourth step is mixed and mixed in a predetermined ratio A fifth step of providing an extract.
본 발명의 다른 측면에 따르면, 흡연으로 인한 유해성분 제거용 생약추출물 의 제조방법은 알로에, 금잔화, 까마중, 삼칠, 녹차엽, 약모밀, 새삼덩굴, 인동덩굴, 감초 및 차전초를 각각 건조하여 건조물을 형성하는 제1단계와, 상기 제1단계의 건조물을 소정의 비율로 혼합하여 혼합 건조물을 제공하는 제2단계와, 상기 제2단계의 혼합 건조물에 수용성 용매를 넣고 가열하여 건조물의 성분이 용매에 추출된 혼합 추출용액을 형성하는 제3단계와, 상기 제3단계의 혼합 추출용액을 여과하여 고형물질을 제거하는 제4단계와, 상기 제4단계에서 여과된 혼합 추출용액에 함유된 용매성분을 증발시켜 혼합추출물을 제공하는 제5단계를 포함한다.According to another aspect of the present invention, the manufacturing method of the herbal extract for removing harmful ingredients due to smoking is dried aloe, marigold, black yam, Samchil, green tea leaf, weak wheat, bird vine, honeysuckle, licorice and tea vinegar to form a dried product, respectively. The first step, and the second step of mixing the dry matter of the first step in a predetermined ratio to provide a mixed dry matter, the water-soluble solvent is added to the mixed dry matter of the second step and heated to extract the components of the dry matter to the solvent A third step of forming a mixed extract solution, a fourth step of filtering the mixed extract solution of the third step to remove solids, and a solvent component contained in the mixed extract solution filtered in the fourth step And a fifth step of providing a mixed extract.
이하에서 본 발명에 따른 흡연으로 인한 유해성분 제거용 생약추출물 및 이의 제조방법의 바람직한 실시예를 상세하게 설명한다.Hereinafter will be described in detail a preferred embodiment of the herbal extract for removing harmful components due to smoking and a method for producing the same according to the present invention.
이들 실시예는 본 발명을 예증하기 위한 것으로서 본 발명의 권리범위는 이들 실시예에만 한정되는 것은 아니다.These examples are intended to illustrate the invention and the scope of the present invention is not limited only to these examples.
본 발명에 따른 흡연으로 인한 유해성분 제거용 생약추출물의 실시예로 알로에 0.5~10 중량%, 금잔화 5~40 중량%, 까마중 5~20 중량%, 삼칠 0.5~10 중량%, 녹차엽 5~20 중량%, 차전초 5~40 중량%, 약모밀 5~40 중량%, 새삼덩굴 5~20 중량%, 인동덩굴 5~30 중량% 및 감초 0.5~10 중량%를 포함한다.Examples of herbal extracts for eliminating harmful components due to smoking according to the present invention include aloe 0.5 to 10% by weight, marigold 5 to 40% by weight, 5 to 20% by weight, 5 to 20% by weight, 0.5 to 10% by weight, green tea leaves 5 to 20 It includes 5% by weight, 5-40% by weight of chajeoncho, 5-40% by weight of weak buckwheat, 5-20% by weight of vines, 5-30% by weight of honeysuckle and 0.5-10% by weight of licorice.
본 실시예에 따른 생약추출물로 이용되는 성분 및 그 작용 효과는 하기와 같으며, 설명의 편의상 각각의 재료에 일련번호를 부여하여 (1)약모밀, (2)새삼덩굴, (3)인동덩굴, (4)감초, (5)금잔화, (6)까마중, (7)알로에, (8)삼칠, (9)녹차엽, (10)차전초의 순서대로 하기에 상세히 설명한다.The ingredients used in the herbal extracts according to the present embodiment and the effects thereof are as follows. For convenience of explanation, each material is assigned a serial number (1) weak wheatgrass, (2) bird vines, (3) honeysuckle, (4) Licorice, (5) Marigolds, (6) Acorns, (7) Aloe, (8) Samchil, (9) Green tea leaves, and (10) Charcoal candles are described in detail below.
성분(1)의 약모밀(Houttuynia cordata Thunb (Polypara cordata Bueck))은 다른 이름으로 중약초, 즙채, 삼백초, 어성초, 십약이라고도 부르며, 식물의 줄기와 잎이 사용된다.Houttuynia cordata Thunb (Polypara cordata Bueck) of ingredient (1) is also called medicinal herb, succulent, three hundred vine, effervescent and ten, and the stem and leaves of the plant are used.
주성분은 메틸노닐케논(CH3(CH2)8COCH3;데카노일 아세트알데히드의 산화 생성물) 미르센(C10H16), 라우린 알데히드(C11H23CHO), 카프린알데히드(C 9H19CHO), 카르프산 등이 있으며 잎에는 쿠에르시트린과 물에 풀리는 무기물이 2.7%가 있다.The main components are methylnonylkenone (CH 3 (CH 2 ) 8 COCH 3 ; oxidation product of decanoyl acetaldehyde) myrcene (C 10 H 16 ), laurin aldehyde (C 11 H 23 CHO), caprinaldehyde (C 9 H 19 CHO), carplic acid, etc., and leaves contain 2.7% of quercitrin and minerals released in water.
작용으로는 쿠에르시트린는 오줌내기 작용(10만배농도)과 강심작용과 대장균, 장티푸스균, 파라티푸스균, 적리균, 임균, 포도알균 및 사상균에 대한 항균작용과 모세혈관 강화작용이 있다.Cuercitrin has urinary action (100,000-fold concentration), cardiac action, antibacterial action against Escherichia coli, typhoid bacteria, paratyphoid bacteria, erythropoies, gonococci, staphylococci and filamentous fungi, and capillary potentiation.
데카노일 아세트알데히드는 비병원성 곰팡이는 물론 백선균, 무좀균 등에 대한 항균작용이 있으며 포도알균, 임균, 항산성균에도 억균작용이 있다. 포도알균에 대한 항균력은 1 : 40,000이며 설파제보다 세다.Decanoyl acetaldehyde has antimicrobial activity against non-pathogenic fungi, as well as ringworm and athlete's foot fungi, as well as fungi against staphylococcus aureus, gonococcus and anti-acid bacteria. Antimicrobial activity against staphylococcus is 1: 40,000 and is stronger than sulfa.
전초는 염증약과 이뇨해독약으로 사용되며, 이뇨해독약으로 임질, 요도염, 방광염, 자궁염, 폐렴, 기관지염, 물고임, 무좀치료, 탈 항, 악창, 풍악 및 축농증 등에 사용된다. 민간처방으로 즙으로 조제하여, 무좀, 치질, 뱀 독 및 옻이 올랐을 때 붙인다. 잎과 줄기는 부기, 각기 등에 오줌내기약으로, 뿌리는 풍독, 종창에 사용된다.Outpost is used as an inflammatory and diuretic detoxification agent, and it is used for gonorrhea, urethritis, cystitis, uterus, pneumonia, bronchitis, bite, athlete's foot, anti-depressive, swelling, windworm and sinusitis. Prepared with juice as a folk prescription, attach when athlete's foot, hemorrhoids, snake venom and lacquer rise. The leaves and stems are urinary medicines for swelling and each other. The roots are used for wind poison and swelling.
성분(2)의 새삼(Cuscuta japonica Choisy)은 씨를 여문것을 따서 햇볕에 잘 말린 것을 사용한다. 성분으로는 씨에는 수지 모양의 배당체, 아밀라제, 프로비타민 A가 약 40mg%, 당이 있고 전초에는 켐페롤이 있다.Cuscuta japonica Choisy of ingredient (2) is picked from the seeds and dried in the sun. Seeds contain about 40mg% of resin-like glycosides, amylase and provitamin A, sugars, and camphorol in the outpost.
동의치료로는 강정강장약으로 음위증, 유정, 허리아픔에 사용되며 진정약, 아픔멎이약, 설사약으로도 사용된다. 민간처방은 전초즙으로 구진(농포)을 없애기 위하여 얼굴을 씻으며 가래약, 피멎이약, 땀내기약, 구풍약, 열물내기약, 가래약, 벌레떼기약, 설사약, 폐렴, 콩팥염 및 고혈압 등의 치료에 사용된다.It is used as a gangjeong tonic for the treatment of gastrointestinal disorders, oil wells, and back pain. It is also used as a sedative, pain medicine, and diarrhea. Folk prescription is to wash the face to remove papules with scallop juice, sputum pill, blood pill, sweat pill, old wind pill, fever pill, sputum pill, insect pest, diarrhea, pneumonia, kidney disease and high blood pressure. Used for the treatment of
성분(3)의 인동덩굴(Lonicera japonica Thunb)은 다른 이름으로 금은화, 겨우살이덩굴 이라고도 부르며 식물의 줄기와 잎을 사용한다.Lonicera japonica Thunb of ingredient (3) is also called gold, silver and mistletoe, and uses the stem and leaves of the plant.
성분으로서는 꽃에는 루테올린(C15H10O6;5,7,3,4-테트라히드록시플라본), 이노시톨 (C6H12O6)이 있으며 꽃이 단 것은 이노시톨 때문이며 납모양 물질(세릴알콜, 스테롤, 아라킨산, 미리스트산, 엘라이딘산, 리놀산, 리놀레산)이 있다.Flowers include luteolin (C 15 H 10 O 6 ; 5,7,3,4-tetrahydroxyflavones) and inositol (C 6 H 12 O 6 ). Flowers are due to inositol and lead-like substances (seryl) Alcohols, sterols, arachnic acid, myristic acid, ellidinic acid, linoleic acid, linoleic acid).
잎과 줄기에는 5~8%의 타닌질이 있고 잎에는 로가닌, 약 19%의 함 질소물질 및 루테올린-7-람노글루코시드인 로니세린(C27H30O15 2H2O)이 있다. 동일한 속 식물(L. morronii)의 잎에서 이리노이드 화합물로 로니세로이드, 스웨로시드가 있다.The leaves and stems contain 5-8% tannins, and the leaves contain loganine, about 19% nitrogen-containing substances, and roniserine (C 27 H 30 O 15 2H 2 O), a luteolin-7-rhamnoglucoside. have. Irinoid compounds in the leaves of the same genus plant (L. morronii) are roniseiroid, sweroside.
꽃 달인 물은 오줌내기 작용과 혈당량을 늘리는 작용과 적리균, 장티푸스균, 포도상구균, 폐렴쌍구균에 억균작용과 소화성위궤양의 예방효과, 교감신경흥분, 평활근마비 작용이 있다.Flower decoction has the effect of urinating and increasing blood sugar and preventing the action of pneumoniae, typhoid, staphylococcus, and pneumococcal pneumoniae, peptic ulcer, sympathetic nerve excitement and smooth muscle paralysis.
동의치료에서 꽃과 잎, 줄기를 열내림약, 독풀이약, 오줌내기약, 정혈약으로 풍악초기에 열날 때, 종창과 종독, 창독, 곪는 질병에 사용되며 달임 약으로는 곪는 질병에 사용된다. 숯처럼 탄 것은 피멎이 약으로 사용된다.In motion therapy, flowers, leaves, and stems are used for fever, poison, urine and sperm medicine in the early stages of wind music. Burnt like char is used as a medicine for blood.
민간처방으로 암 치료에 사용된다. 물에 달여 차처럼 오래 음용하면 위암과 자궁내막염, 림프절결핵의 누공, 입안염에 효과적이다.It is used for the treatment of cancer as a private prescription. Drinking water for a long time like tea is effective for gastric cancer, endometritis, fistula of lymph node tuberculosis and ophthalmitis.
성분(4)의 감초(Glycyrrhiza glabra L.)는 국로, 곧은감초, 민감초라고도 불리우며 감초의 뿌리를 사용한다. 가을에 뿌리줄기와 뿌리를 캐어 줄기를 다듬고 물에 씻어서 햇볕에 말려서 사용된다. 뿌리줄기와 뿌리의 글리시리진 함량은 여름보다 가을에 높고 2년생 감초의 글리시리진 함량은 4월에 3.8%, 5월에 3.7%, 7월에 3.3%, 8월에 3.8%, 9월에 5%, 10월에 6% 이다. 뿌리의 부위에 따른 글리시리진 함량을 보면 2년생 감초의 원뿌리(주근)에 6.91%, 가는 뿌리에 8.04% 이다. 그러므로 원뿌리와 뿌리줄기에 잔뿌리를 포함시켜 이용하는 것이 바람직하다. 또한 껍질(13.06%)은 목부와 수심(10.42%)보다 그 함량이 높다. 껍질을 벗길 때에는 코르크화된 겉껍질만을 벗기고 되도록 속껍질을 상하지 않게 하여야 한다. 성분으로서는 뿌리와 줄기에는 글리시리진(글리시리진산의 칼륨염 또는 칼슘염)이 5~14%이고 많은 것은 23%이며, 글라브라산(글리시레틴;C30H46O5)이 있다.The licorice (Glycyrrhiza glabra L.) of the ingredient (4) is called a national dish, straight licorice, a sensitive herb and uses the root of licorice. In the fall, root stems and roots are carved out, trimmed, washed in water and dried in the sun. Root stem and root glycyrrhigen content is higher than summer, and biennial licorice content is 3.8% in April, 3.7% in May, 3.3% in July, 3.8% in August, 5% in September, 6% in October. According to the parts of the roots, the content of glycyrrhizin is 6.91% in the root of the biennial licorice and 8.04% in the thin root. Therefore, it is preferable to use small roots in the root and root stem. Also, the skin (13.06%) is higher than the neck and water (10.42%). When peeling, only the corked skin should be peeled off, so that the skin is not damaged. Roots and stems contain 5-14% glycyrrhizin (potassium or calcium salt of glycyrrhizin), many 23%, and glabraic acid (glyciretin; C 30 H 46 O 5 ).
글리시리진산C42H62O16은 트리테르페노이드사포닌으로 녹는점 205℃, 분해점 220℃, [d]D 20 +58.5℃이고 알코올과 뜨거운 물에 잘 풀리며 에테르에 풀리지 않는다. 뜨거운 물에 푼 것을 식히면 갖풀처럼 굳어진다. 물 분해하면 맛이 없는 글리시레틴산 (C30H46O4)과 2분자의 글루쿠론산(C6H10O 7)이 생긴다. 글리시레틴산은 β-아미린계 트리테르페노이드로 α,β체의 2가지가 있는데 쉽게 서로 변한다. 그러나 그의 에스테르는 서로 변화하지 않는다. α-글리시레틴산은 판 모양 결정의 묽은알콜이고 녹는점 283℃, [d]D 20 +140℃(에탄올)이고 에탄올, 디옥산, 클로로포름에 풀린다. β-글리시레틴산은 바늘결정(에탄올)이며 녹는점 296~300℃, [d]D 20 +86℃ (알코올)이고 에탄올, 피리딘, 초산에 풀리고 석유에테르에 잘 풀리지 않는다.Glycilisic acid C 42 H 62 O 16 is triterpenoid saponin, melting point 205 ℃, decomposition point 220 ℃, [d] D 20 + 58.5 ℃, well soluble in alcohol and hot water and not soluble in ether. After cooling in hot water, it hardens like grass. Decomposition of water results in tasteless glycyrrhetinic acid (C 30 H 46 O 4 ) and two molecules of glucuronic acid (C 6 H 10 O 7 ). Glycyretinic acid is a β-amirin-based triterpenoid, which has two kinds of α and β substances, which are easily changed. But its esters do not change from one another. α-glyciretinic acid is a dilute alcohol of plate crystals, melting point 283 ° C, [d] D 20 + 140 ° C (ethanol) and solved with ethanol, dioxane and chloroform. β-Glycyretinic acid is needle crystal (ethanol), melting point 296 ~ 300 ℃, [d] D 20 + 86 ℃ (alcohol), soluble in ethanol, pyridine, acetic acid and not soluble in petroleum ether.
또한 플라보노 배당체인 리쿠이리틴 C21H22O9, 네오리쿠이리틴, 람노리쿠이리틴(이것들의 비당부분은 모두 리쿠이리티게닌 이다)과 이에 대응되는 갈콘 배당체로 이소리쿠이리틴, 네오이소리쿠이리틴, 이소람노리쿠이리틴, 리쿠라시드(이것들의 비당 부분은 모두 이소리쿠이리티게닌 이다)가 있다. 람노리쿠이리틴을 리쿠이리토시드라고도 한다.In addition, flavono glycosides, liqueurin C 21 H 22 O 9 , neoriquiritin, and lamnoricuritin (these non-sugar parts are all liqueurininin) and the corresponding galcon glycosides, such as isoricuitin and neo Isoricuiritin, isoram norikuiritin, and liqueur seed (the non-sugar part of these are all Isorikuuritingenin). Rhamnoricuritin is also called liqueuritoside.
감초뿌리에서 크로마토그래프로 27개가 넘는 플라보노이드 유사물질이 확인 되었다. 굽은 감초 뿌리에서는 β-시토스테롤, 포르모노네틴, 리코리시딘, 리코리콘, 리코레올리그난이 확인 되었다. 또한 꽃필 때의 마른 잎과 줄기에는 단백질 14~22%, 기름 2~5%, 무질소엑스 36~62%, 회분 5~20%로 집짐승 먹이로 사용된다.Chromatographs from licorice root identified more than 27 flavonoid analogs. Β-sitosterol, formmononetin, ricolycidine, lycoricone, and ricore-oligonane were identified in the roots of curved licorice. In addition, 14 to 22% protein, 2 to 5% oil, 36 to 62% nitrogen-free extract, and 5 to 20% ash are used for feeding beasts on dry leaves and stems when flowering.
감초의 플라보노이드 함량은 자라는 시기에 따라 변한다. 뿌리는 가을철, 잎과 줄기는 열매가 달리기 시작할 때 제일 높다. 가을철 리쿠라시드의 함량은 약 0.5%이다. 리쿠라시드는 총플라보노이드의 약 10%을 차지한다.Flavonoid content in licorice changes with the season of growth. The roots are high in autumn and the leaves and stems are highest when the berries begin to run. The content of liqueur seeds in autumn is about 0.5%. Licuraside accounts for about 10% of the total flavonoids.
줄기와 잎에 사포나레틴, 글리포시드, 비텍신 등이 있다. 사포나레틴은 총플라보노이드의 약 50%이며 열매가 열릴 때의 전초에 3% 함유되어 있다.There are saponaretin, glyphoside and bitexin on the stem and leaves. Saponaretin is about 50% of the total flavonoids and 3% in the outpost when fruit is opened.
또한 쓴맛이 있는 글리시라마린(글리시리진의 쓴맛 성분), 2,4,4-트리히드록시갈콘과 그 배당체 디옥시스티그마스테롤(녹는점135~136℃), β-시토스테롤, 정유(0.03%), 아스코르빈산 11~30mg%, 아스파라긴(1~4%), 과당 (2.4~6.5%), 포도당 (2~4%) 만니톨, 녹말 (14~30%), 고무질 (1.5~4%), 노란색소, 사과산, 기름, 수지, 타닌, 단백질과 아스파라긴산, 프롤린, 알라닌, 트레오닌, 세린, 글리신, 발린, 이소류신, γ-아미노버터산을 포함하는 아미노산이 있다. 쓴맛이 제일 강할 때는 8%이다. 이중 물에 풀리는 것이 2.5~3%이다.Glyceramarin (bitter component of glycyrrhizine), 2,4,4-trihydroxygalcon and its glycosides Dioxystigmasterol (melting point 135 ~ 136 ℃), β-sitosterol, essential oil (0.03%), Ascorbic Acid 11-30mg%, Asparagine (1-4%), Fructose (2.4-6.5%), Glucose (2-4%) Mannitol, Starch (14-30%), Gum (1.5-4%), Yellow There are amino acids including bovine, malic acid, oil, resin, tannin, protein and aspartic acid, proline, alanine, threonine, serine, glycine, valine, isoleucine, and γ-aminobutyric acid. The strongest bitter taste is 8%. Among them, 2.5 ~ 3% of the water is released.
글리시리진은 감초 뿌리의 유효성분으로 알려져 있으며 사탕의 40~50배 정도로 단맛이 있으며 그 단맛은 10만 배의 희석액에서도 느낄 수 있다. 물 용액은 흔들면 거품이 생기지만 일반 사포닌보다 약하고 용혈작용도 없거나 약하다(칼륨염은 1 : 400). 글리시리진의 물 분해에 의하여 생긴 글리시레틴산은 단맛이 없고 용혈작용이 있다. 그리하여 감초의 거담 작용은 글리시레틴산에 의한 것으로 추정된다. 글리시리진은 또한 호흡기를 완화 시킨다.Glycirizine is known as an active ingredient of licorice root and has a sweet taste of about 40-50 times that of candy, and its sweetness can be felt even in a dilution of 100,000 times. The water solution foams when shaken, but is weaker than normal saponins and has no or hemolytic action (potassium salt is 1: 400). The glycyrrhetinic acid produced by the hydrolysis of glycyrrhizin is not sweet and hemolytic. Thus, the expectorant action of licorice is presumed to be due to glycyrrhetinic acid. Glysirizine also relieves the respiratory system.
감초뿌리엑스, 글리시리진은 독성이 없고 포수클로랄, 스트리크닌, 요힘빈, 코카인, 모르핀, 코데인, 아트로핀, 루미날 등에 의한 중독을 풀어준다. 세균독과 바이러스독, 예를 들면 파상풍 독소, 디프테리아 독소, 뱀 독을 풀어준다.Licorice root extract and glycyrrhizin are non-toxic and relieve poisoning by catcherchloral, strycnin, yohimbine, cocaine, morphine, codeine, atropine and luminal. Releases bacterial and viral toxins such as tetanus toxin, diphtheria toxin and snake venom.
아세틸콜린, 히스타민, 알레르기를 일으키는 물질과는 길항작용을 하며 아드레날린과 비슷한 강심작용도 있다.It antagonizes with acetylcholine, histamine, and allergens, and has an adrenaline-like effect.
글리시리진의 독풀이 작용은 물 분해 산물인 글루쿠론산과 관계된다. 글루쿠론산은 동식물계에 널리 들어있는 성분으로 간에서 유독한 물질과 결합되어 글루쿠 로니드를 형성하고 오줌으로 배설된다. 그러므로 글루쿠론산은 약물중독, 알코올중독, 식중독, 황달, 간경변증, 만성간장에, 류머티즘, 관절아픔, 신경아픔 등에 쓰이고 있다. 글리시리진의 독풀이작용은 글루쿠론산 뿐만아니라 글리시리진의 부신피질호르몬의 작용과 관계된다. 즉, 글리시리진은 부신피질 호르몬인 데스옥시코르티코스테론과 유사한 효과를 갖는다.The poisonous action of glycyrrhizin is related to glucuronic acid, a product of water degradation. Glucuronic acid is a component widely found in animal and plant systems and is combined with toxic substances in the liver to form glucuronide and excreted by urine. Therefore, glucuronic acid is used for drug addiction, alcoholism, food poisoning, jaundice, cirrhosis of the liver, chronic liver, rheumatism, joint pain, nerve pain. The detoxification of glycyrrhizin is related to the action of glucuronic acid as well as the corticosteroids of glycyrrhizin. In other words, glycyrrhizin has an effect similar to that of the adrenal cortex hormone desoxycorticosterone.
글리시레틴산은 동물실험에서 나트륨과 클로르, 오줌의 배설량을 줄이고 칼륨의 배설량을 늘린다. 즉, 나트륨과 칼륨(Na/K)의 비를 낮춘다. 이와 같이 칼륨대사에는 부정적 영향을 주지만 나트륨대사에는 긍정적 영향을 준다. 또한 물과 염류대사에 대한 부신피질 호르몬의 영향을 강화할 수 있도록 부신피질의 아스코르브산 함량을 줄이는 작용을 한다. 이러한 작용은 감초의 추출물과 글리시리진에 있다. 사람이 먹었을 때 동일한 작용이 나타난다.Glycyretinic acid reduces the excretion of sodium, chlorine and urine and increases the excretion of potassium in animal experiments. That is, the ratio of sodium and potassium (Na / K) is lowered. As such, it negatively affects potassium metabolism but positively affects sodium metabolism. It also acts to reduce the ascorbic acid content of the adrenal cortex to enhance the effects of corticosteroids on water and salt metabolism. This action is found in licorice extract and glycyrrhizin. The same thing happens when a person eats.
감초뿌리엑스 글리시리진은 항염증 작용을 한다. 동물에게 실험적으로 일으킨 포르말린 관절염의 치료에 긍정적 영향을 준다. 혈청 트랜스아미나제의 활성을 억제하며 간에 있는 아데노신트리포스파타아제의 활성을 높이고, 글리시리진의 데스옥시코르티코스테론과 비슷한 항염작용은 분해 산물인 글리시레틴산에 의한 것이 다.Licorice root extract glycyrrhizin is anti-inflammatory. It has a positive effect on the treatment of formalin arthritis caused experimentally in animals. It inhibits the activity of serum transaminase, increases the activity of adenosine triphosphatase in the liver, and anti-inflammatory action similar to the desoxycorticosterone of glycyrrhizine is due to its degradation product glycyrrhetinic acid.
글리시리진의 부신피질호르몬 유사작용은 코르티코이드의 생체 안에서의 비활성화 Δ4-3케톤부분의 환원을 억제하기 때문이라는 견해도 있다.There is also a view that the corticosteroid-like action of glycyrizine inhibits the reduction of the inactivating Δ 4 -3 ketone moiety in vivo.
감초뿌리엑스는 동물실험에서 위장평활근에 대한 파파베린과 비슷한 항 근육 성 진경작용이 있다. 이작용은 플라보노이드 성분에 기인한다. 감초의 플라보노이드는 지금까지 쓰이지 않았던 것인데 진경작용, 항염증작용이 알려지면서 개발되었다. 플라보노이드 성분인 리쿠라시드는 파파베린보다 3배나 센 진경작용이 있으면서도 항염증, 항궤양활성이 있다. 그리고 아세틸콜린, 히스타민에 대한 길항작용이 있다.Licorice root extract has an anti-muscular effect similar to papaverine on gastrointestinal smooth muscle in animal experiments. This action is due to the flavonoid component. Licorice flavonoids, which have not been used until now, was developed with known antifungal and anti-inflammatory effects. Licuraside, a flavonoid component, has three times as hard as papaverine and has anti-inflammatory and anti-ulcer activity. And antagonists of acetylcholine and histamine.
감초뿌리엑스가 소화성위궤양에 치료효과가 있다는 것은 1950년대에 알려짐에 따라 감초뿌리에서 항궤양성 물질을 찾아내기 위한 많은 실험이 진행되었다. 1960년대 들어와서 플라보노이드를 얻어내고 플라보노이드 성분이 진경작용을 한다는 사실을 확인 하였다. 또한 최근에 많은 실험들을 통하여 진경작용뿐만 아니라 항 염증작용, 항궤양성작용이 있다는 것이다.Licorice root extract has been known to have a therapeutic effect on peptic gastric ulcers in the 1950s, and many experiments have been conducted to find anti-ulcer substances in licorice roots. In the 1960's, flavonoids were obtained and flavonoids were found to be active. In addition, recent experiments have shown that there are anti-inflammatory and anti-ulcerative effects as well as palliative action.
감초는 계면 활성이 세므로 다른 동약재와 달이거나 먹으면 동약성분을 물에 잘 풀리게 하여 흡수를 돕는다. 또한 동약재의 독성을 줄이고 맛을 바꾼다 요즘에는 에스트로겐 작용도 주목 되고 있다. 감초뿌리에는 포도알균, 대장균, 적리균에 억제작용이 있다. 글리시리진산을 항암약인 티오폭스마미드와 함께 쓰면 항암 활성은 85~95%가 나타난다. 감초뿌리의 작용은 가래삭임작용, 완화작용, 항 염증작용과 진경작용, 항히스타민작용 등이 있다.Licorice has a strong surface activity, so if you eat it with other copper medicines, it helps loosen the ingredients in water to help absorption. It also reduces the toxicity of the medicinal herbs and changes the taste. Licorice root has an inhibitory effect on staphylococcus aureus, Escherichia coli, and bacilli. When glycyrrhizin is used with anti-cancer drug thiopoxamide, anti-cancer activity is 85-95%. Licorice root's actions include sputum cutting, alleviating, anti-inflammatory and jingyeong, and antihistamine.
따라서 가래기침약으로 상기도 질병에 사용된다. 단맛이 있으므로 약품의 약고침약으로도 사용된다. 독풀이약이나 부형약으로도 사용된다. 요즘에는 위십이지장궤양, 에디슨 병, 기관지천식, 황달과 간염, 습진을 비롯한 피부병 등에 널리 쓰이고 있다. 글리시리진산은 항암약의 활성을 높이기 위한 보조약으로 사용된다.Therefore, it is used for upper respiratory tract disease as sputum aggression. Because of its sweetness, it is also used as a drug-inhibiting agent. It can also be used as a poison or medicine. Nowadays, it is widely used for gastroduodenal ulcers, Edison disease, bronchial asthma, jaundice and hepatitis, eczema and other skin diseases. Glycilisic acid is used as a supplement to increase the activity of anticancer drugs.
동의치료로는 감초뿌리를 다른 동약들의 작용을 완화 및 조화시킬 목적으로 사용된다. 즉 더운약과 같이 쓰면 열을 완화 시키며 찬약과 같이 쓰면 찬 것을 완화시킨다. 이처럼 완화 약 또는 아픔멎이진경약, 가래 약, 기침멎이약, 독풀이약으로 위경련, 위아픔, 인후아픔, 위궤양 및 십이지장궤양 등에 쓰며 독이 있는 동의처방에 사용된다.In ligament therapy, licorice root is used to alleviate and harmonize the effects of other medicines. In other words, when used with a hot medicine to relieve heat, and when used with a cold to relieve the cold. Like this palliative medicine or pain 멎 jinyongjeok, sputum medicine, cough 멎 yigeok, poison grass medicine is used for stomach cramps, stomach pain, sore throat, stomach ulcer and duodenal ulcer and used in the prescription of the poisonous consent.
성분(5)의 금잔화(Calendula officinalis L.)는 금송화라고도 불리우며, 금잔화의 꽃잎을 따서 그늘에 말린 것을 사용한다. 주성분으로는 카로틴, 리코핀(녹는점175℃), 비올라크산틴(C40H56O4;녹는점207~208℃), 루비크산틴(녹는점160℃), 네오리코핀A, 시트라크산틴(녹는점163~164℃), 클라보크롬(녹는점184~185℃)과 같은 플라보노이드가 있다. 카로티노이드의 함량은 약 3%이다. Calendula officinalis L. (5), also called calendula, uses the petals of marigold and dried in the shade. The main ingredients are carotene, lycopene (melting point 175 ℃), violaxanthin (C 40 H 56 O 4 ; melting point 207 ~ 208 ℃), rubyxanthin (melting point 160 ℃), neoricopin A, citraxanthin ( Flavonoids such as melting point 163 ~ 164 ° C) and clavochrome (melting point 184 ~ 185 ° C). The content of carotenoids is about 3%.
꽃에는 정유가 0.02%, 수지 약 3.4%(이가운데 함질소점액은 1.5%), 알부민 0.64%, 사과산으로 계산한 유기산 6.84%, 적은양의 살리실산, 알칼로이드가 있다. 지상부에는 쓴맛 물질인 칼렌덴 (C23H38O7), 사포닌(물분해하면 올레아놀산과 글루쿠론산이 된다), 불포화트리테르펜디올인 아르니디올, 파라디올, 타닌질(6~7%)이 있다. 씨에는 알칼로이드, 기름(주로 라우릴산과 팔미트산의 글리세리드), 기름의 비누화 되지 않은 부분에 세릴알코올, 피토스테롤이 있다.Flowers contain 0.02% essential oils, about 3.4% resins (about 1.5% nitrogen content), albumin 0.64%, organic acids calculated from malic acid 6.84%, small amounts of salicylic acid and alkaloids. Above ground, calenden (C 23 H 38 O 7 ), saponin (when decomposes into oleanolic acid and glucuronic acid), arnidiol, paradiol, tannin (6-7%), unsaturated triterpenediol There is this. Seeds include alkaloids, oils (primarily glycerides of lauric acid and palmitic acid), and seryl alcohol and phytosterol in the unsaponified portion of the oil.
작용으로는 꽃 달인액과 알코올추출물, 생즙은 동물실험에서 중추신경계통에 대한 진정작용이 있고 반사 흥분성을 낮춘다. 또한 혈압을 내리고 심장 수축을 세게 하며 심장의 율동을 느리게 하고 살균작용을 한다.As a function, flower decoction, alcohol extract, and juice have a calming effect on the central nervous system in animal experiments and lower reflex excitability. It also lowers blood pressure, hardens heart contractions, slows heart rhythms and sterilizes.
고약을 만들어 화상, 궤양, 치열(관장한다), 뾰두라지몰림, 뾰두라지에 바른다. 또한 우림약과 팅크는 입안염, 치조농루에 입가심하고 자궁루, 자궁경부미란, 트리코모나스성 질염에 씻는다(2%팅크). 우림약과 팅크는 위 십이지장궤양과 간염, 당남염, 당낭염에 염증약, 열물내기약으로 사용된다. 고혈압과 심장병에도 사용된다. 꽃가루와 니코틴산을 섞은 것은 수술할 수 없는 위암에 치료약으로 사용된다. 상기와 같은 약을 쓰면 중독증상과 소화불량, 트림, 구역질이 적어지고 밥맛이 좋와지며 잠이 잘온다. Make a plaster and apply it to the burns, ulcers, dentitions, crows, and crows. Also, rainforest medicine and tinctures are affected by ophthalmitis, alveolar pylori and uterine fistula, cervical erosion, and trichomoniasis vaginitis (2% tincture). Rainforest medicine and tincture are used for gastric duodenal ulcers, hepatitis, streptococcitis, and saccharitis as inflammatory drugs and fever-fighting drugs. It is also used for high blood pressure and heart disease. The combination of pollen and nicotinic acid is used as a cure for inoperable stomach cancer. If you use such drugs, symptoms of intoxication, indigestion, burping, nausea are reduced, the taste of rice is good, and sleep is good.
성분(6)의 까마중(Solanum nigrum L.)은 깜뚜라지, 용규, 까마종이 라고도 불리우며 까마중의 열매는 둥글고 검은색으로 익는다. 전초(까마중)를 꽃필 때 줄기를 베어 그늘에 말려서 사용한다.The solanum nigrum L. of the ingredient (6) is also called the crow, larvae, and crow. The fruit of the crow is round and ripe in black. When blossoming outposts, cut the stems and dry them in the shade.
주성분으로는 전초에 스테로이드알칼로이드와 적은 양의 아트로핀, 니코틴이 있다. 스테로이드알칼로이드는 솔라닌(C45H73O15 N;솔라니딘-β-l-람노시드-d-갈락토시드-d-글루코시드), 솔라소딘, 솔라니그린 등이 있다. 전초에는 또한 플라보노이드, 루틴, 아스파라긴, 솔란구스틴, 시토스테롤 7~10%의 타닌질, 사포닌(디오스게닌, 티고게닌), 유기산이 있다. 선열매에도 전초에서와 비슷한 성분이 있다. 익은 열매에는 글리코알칼로이드, 사포닌과 안토시안 색소, β-카로텐, (카로틴으로 318~503mg%), 1,630mg%의 아스코르브산이 있고, 또한 솔라소닌(0.2%), 솔라마르긴(0.25%)이 있다. 잎에는 24~184mg%의 아스코르브산 50mg%의 카로틴이 있다. 뿌리에도 알칼로이드와 사포닌이 있다. The main ingredients in the outpost are steroid alkaloids, small amounts of atropine and nicotine. Steroidal alkaloids include solanine (C 45 H 73 O 15 N; solanidine-β-l-rhamnoside-d-galactosid-d-glucoside), solasodine, solanigrin and the like. Outposts also include flavonoids, rutin, asparagine, solangustin, cytosterol 7-10% tannins, saponins (diosgenin, tigogenin), and organic acids. Coconut has similar ingredients to the outpost. Ripe fruits include glycoalkaloids, saponins and anthocyanin pigments, β-carotene (318-503 mg% as carotene), 1,630 mg% ascorbic acid, and also solonanin (0.2%) and solamargin (0.25%). The leaves contain between 24 and 184 mg of ascorbic acid and 50 mg of carotene. The roots also contain alkaloids and saponins.
작용으로는 전초 달인물은 티푸스균, 포도알균, 녹농균, 적리균, 대장균, 진균에 대한 억제작용과 항염증, 혈당낮춤 작용이 있다. 알칼로이드 성분은 폐나 기관지 조직 중의 히스타민 분해를 촉진시키므로 기침멎이, 가래삭임작용이 있고 혈압을 낮추는 작용이 있다. 매우 적은 양의 아트로핀은 눈동자를 크게 하므로 눈 조절작용의 약한 마비로 오는 심한 바투보기 환자에게 일시적이나마 시력을 좋게 할 수 있다.As a function of the outpost decoction is typhoid bacteria, staphylococcus aureus, Pseudomonas aeruginosa, E. coli, E. coli, fungi, anti-inflammatory, blood sugar lowering action. Alkaloids promote histamine degradation in lung and bronchial tissues, so coughing, sputum sputum and blood pressure lowering. Very small amounts of atropine make the pupils larger, which may result in better vision, even temporarily, in patients with severe Batu Boi who suffer from mild paralysis of eye control.
동의치료에서 강장약, 열내림약, 오줌내기약으로 피로를 회복하는 데 사용된다. 잎과 줄기는 여러가지 상처, 곪은 데 붙이며 열매는 눈을 밝게 한다. 민간에서는 강장약, 오줌내기약으로 신석중, 물고임에 사용된다. 전초즙은 진정약, 진경약, 땀내기약으로 감기에 사용된다. 꽃은 가래약으로, 잎은 수렴약, 피멎이약으로 설사, 적리, 간비대에 사용된다. 잎과 열매 우린액은 방부약, 염증약으로 치질, 궤양, 상처, 부스럼, 버짐, 습진, 뽀두라지, 단독, 선병 등에 사용된다. 또한 아픔멎이약으로 머리아픔, 류머티즘, 통풍, 종양에 사용된다 In motion therapy, it is used to relieve fatigue with tonic, fever and urine medicines. Leaves and stems are attached to various wounds and cuts, and fruit brightens the eyes. In civilian use, it is used as a tonic and urinary medicine for sinseokjung and bite. Starch juice is used for colds as a sedative, cough and sweating medicine. Flowers are sputum, leaves are astringents, blood drops and diarrhea. Leaf and Fruit Weinum is an antiseptic and inflammatory drug used for hemorrhoids, ulcers, wounds, swelling, ringworm, eczema, navel, soles, and strokes. It is also used for head pain, rheumatism, gout and tumor.
성분(7)의 알로에(Aloe sp)로 알로에속 식물은 약 170종이 알려져 있다. 짧은 줄기위에 많은 잎이 모여 난다. 잎은 살졌고 가장자리에 가시가 있다. 흰색, 노란색, 붉은색 꽃이 이삭처럼 모여 핀다. 열대지방에서 자라는 것은 높이 4m, 잎의길이 65cm에 이른다. 알로에는 산지에 따라 기원식물이 다르다. 우리나라에서 온실에 기르는 것은 긴잎알로에A.arborescens, 얼룩잎알로에A.saponaria, 넓은잎 알로에A.arborescens var natalensis 이다. 주성분으로는 알로에(잎즙)에는 알로 인(C20H18O9,;알로에에모딘-d-아라비노시드)16~20%, 알로에-에모딘 나탈로인, 라바르베론(이소에모딘), 수지12%(알로레시노탄놀 C22H26O6 의 계피산에스테르)가 들어 있다.About 170 species of Aloe spp. Are known as Aloe sp of component (7). Many leaves gather on short stems. The leaves are live with thorns on the edges. White, yellow and red flowers gather together like Isaac. Growing in the tropics reaches 4m high and leaves 65cm long. Aloe plants differ in origin depending on the region. In Korea, long-leaved aloe A. arborescens, speckled leaf aloe A. saponaria, broad-leaf aloe A. arborescens var natalensis. Aloe (leaf juice) contains aloe phosphate (C 20 H 18 O 9 , aloe emodine-d-arabinoside) 16-20%, aloe-emodin natalo, labarberon (isoemodine) And 12% of resin (cinnamic acid ester of allolecinotanol C 22 H 26 O 6 ) is contained.
알로에(잎즙을 말린 것)는 쓴맛강장약, 소화 및 식욕항진약으로 한번에 0.02~0.05g, 약한 설사약으로 한번에 0.02~0.2g, 센 설사약으로 한번에 0.3~0.5g을 음용한다. 동의치료에서는 어린이 감적, 변비에 하루 1~2g을 사용된다. Aloe (dried leaf juice) is bitter tonic, digestive and appetite suppressant at 0.02 ~ 0.05g at one time, weak diarrhea at 0.02 ~ 0.2g at once, and strong diarrhea at 0.3 ~ 0.5g at once. In motion therapy, 1-2g is used for children's markers and constipation.
알로에생즙: 즙을 짜서 방부 목적으로 20% 되게 에탄올을 넣은 생즙은 억균약으로 상처를 관장하거나 썩는 염증 부위를 씻는 데 사용된다. 알로에 잎: 생물원자극소를 만들어 사용된다. 생잎을 썰어서 불리한 조건, 즉 어둡고 낮은 온도에 12일 동안 둔다. 이때 생잎에는 불리한 생활 조건으로 하여 약해지는 생명활동을 자극하는 물질이 생긴다고 한다. 이 물질을 생물원자극소라고 이름 지었는데 그 화학적 조성은 아직 밝혀지지 않았다. 대체로 지방족 디카르복시산, 분자량이 큰 방향족 유기산으로 보고 있다. 이렇게 처리한 잎을 분쇄기로 짓찧어 방온도에서 3배량의 물을 넣어 놓아두었다가 거른 다음 멸균하여 주사약을 제조한다. 또는 잎즙과 기름으로 젖제도 제조한다. 주사약은 환자의 방어기능을 높이는 데 쓰며 젖제는 방사선 피해 때 피부손상을 막기위하여 사용된다. 알로에 즙: 생물원자극소로 신선한 알로에즙 80㎖에 95% 에틸알코올 20㎖, 클로르부탄올히드라트 0.5%함량으로 섞는다. Aloe juice: Fresh juice containing 20% ethanol for squeezing juice is used as a fungicide to clean wounds or rotted areas of inflammation. Aloe leaf: used to make biostimulants. Slice the raw leaves and leave for 12 days in adverse conditions, ie dark and low temperatures. At this time, the leaves are said to produce substances that stimulate the vital activity weakened due to adverse living conditions. This material was termed a biostimulator, and its chemical composition is still unknown. It is generally regarded as an aliphatic dicarboxylic acid and an aromatic organic acid having a large molecular weight. The treated leaves are crushed with a grinder, placed in a volume of 3 times water at room temperature, filtered and sterilized to prepare injections. Or lactose and oil are also prepared. Injectables are used to enhance the patient's defenses, while lactose is used to prevent skin damage during radiation damage. Aloe juice: As a bio-irritant, mix 80 ml of fresh aloe juice with 20 ml of 95% ethyl alcohol and 0.5% chlorbutanol hydrat.
위염, 위장염, 대장염, 변비에 작은 숟갈로 한 숟갈 또는 반숟갈을 하루에 2~3번씩 밥 먹기 30분 전, 15~30일 동안 복용한다. 상처, 화상, 피부와 점막염증 치료에 띠고 바르기도 한다. 알로에 유동엑스주사약은 위십이지장궤양, 만성폐렴, 기관지천식, 눈병과 그 밖의 질병에 사용된다.For gastritis, gastroenteritis, colitis, constipation, take a small spoonful or half a tablespoon two to three times a day for 30 minutes, 15 to 30 days before eating. It can also be applied to the treatment of wounds, burns, skin and mucositis. Aloe X extract is used for gastroduodenal ulcers, chronic pneumonia, bronchial asthma, eye diseases and other diseases.
성분 (8)의 삼칠(Panax notoginseng(Burk)F.H.Chen은 금불환, 인삼삼칠, 삼삼칠, 전삼칠, 산칠이라고 불리우며, 삼칠의 뿌리에는 3~8%의 사포닌이 있다.Panax notoginseng (Burk) F.H.Chen of ingredient (8) is called Geumhwanhwan, Ginsengsamchi, Samsamchil, Jeonsamchil, Sanchil, and 3 ~ 8% of saponin at the root of Samchil.
주성분으로는 진세노사이드Rb1, Rg1, Rg1 이며, 적은 양의 진세노사이드 Ra, Rb2, Rd, Re, Rc가 있고, Ro는 없거나 매우 적다. 정유의 조성 성분은 인삼보다 적다.The main components are ginsenosides Rb 1 , Rg 1 , Rg 1 , and there are small amounts of ginsenosides R a , R b2 , R d , R e , R c , and R o is very little. The composition of essential oils is less than ginseng.
뿌리는 피멎이작용, 강심작용이 있다. 동물실험에서 심장동맥의 피 흐름을 늘이고 심근의 산소소비량을 줄이며 피속의 지질과 콜레스테롤의 양을 줄인다. 뿌리를 협심증 심근경색 고혈압 과콜레스테롤혈증에 사용된다. 또한 만성 및 급성 간염에도 사용된다. 중국에서 뿌리를 피멎이약 아픔멎이약 염증약 곪은 것을 낮게 하는 약으로 사용된다. 특히 피멎이 효과가 뚜렷하여 베인상처, 코피, 여성들의 여러가지 피나기에 사용된다. 이 식물은 민간에서 피멎이 약으로 쓰였다. 3개의 가지에 7에의 잎이 붙었다고 하여 삼칠, 그 모양이 조선인삼과 비슷하다고 해서 삼칠인삼이라 하였다. 뿌리를 캐어 잔뿌리를 다듬고 말린 것을 생삼칠, 밀랍으로 곁면에 율기를 낸 것을 숙삼칠이라 한다.Root is bloody, strong heart. In animal experiments, it increases blood flow in the coronary arteries, reduces oxygen consumption in the myocardium, and reduces the amount of lipids and cholesterol in the blood. The root is used for angina myocardial infarction hypertension hypercholesterolemia. It is also used for chronic and acute hepatitis. In China, roots are used as drugs to lower the pain, pain, and inflammation. In particular, the blood effect is obvious, it is used in cuts, nosebleeds and various kinds of women's blood. This plant was used as a bloody medicine in folklore. Samchil is called three-branch leaves with seven leaves, and its shape is similar to Chosun Ginseng. The roots are trimmed and the roots are trimmed and dried ginseng and beeswax with rhythm on the side.
성분 (9)의 차나무(Thea sinensis L)는 사철푸른 떨기나무이며, 잎은 두껍고 긴 타원형이고 가을에 흰 꽃이 피고 열매는 납작한 둥근 모양이고 3개의 모서리가 있다. 전라도, 경상도에 절로 자라는 것이 있으나 흔히 심어 기른다. 또한 가공 방법에 크게 녹차, 홍차, 꽃차(화차)로 나뉜다.Thea sinensis L of component (9) is a evergreen evergreen tree, leaves are thick and long oval, white flowers bloom in autumn, and fruits are flat round shape and have three corners. Jeolla-do, there are some that grow in Gyeongsang-do, but they are often planted. In addition, the processing method is largely divided into green tea, black tea, flower tea (hwacha).
녹차는 잎을 따서 중기로 찌거나 뜨거운 바람으로 산화효소를 비활성화 시킨 다음 말린다. 봄에 싹이 돋아날 때 햇빛을 가려 타닌질이 생기지 못하게 하고 배양한 새싹을 따서 중기에 찐 다음 말린 것을 옥토라고 하는데 단맛이 있다. 홍차는 잎을 따서 절반 말린 다음 짓찧어 하룻밤 쌓아둔다. 이때 효소의 작용으로 타닌질이 산화되어 붉은색을 띤다. 이것을 뜨거운 바람으로 말린 것이다. 꽃차는 잎과 꽃을 섞어서 쌓아두어 꽃향기를 잎에 흡수시킨 다음 말린 것인데 향기가 있다. Green tea is picked and steamed in medium or inactivated by oxidizing enzymes with hot air and then dried. When the shoots sprout in spring, they block the sunlight to prevent tannins, and after picking the cultivated shoots, they are steamed in the middle and dried. Black tea is picked and dried in half, then crushed and stacked overnight. At this time, the tannin is oxidized by the action of the enzyme to have a red color. This is dried by hot wind. Flower tea is a mixture of leaves and flowers, piled up, absorbed with floral fragrance, and dried.
주성분으로는 잎에는 카페인(C8H10O2N4), 크산틴(C5H 4O2N4), 테오필린과 같은 푸린염기가 1~6% 있다. 또한 차나무 타닌이 9~15%있다. 그 가운데서 가용성 타닌은 약3%, 불용성 타닌은 9.9%이다. 차나무 타닌(C22H18O10)은 테아카테콜의 몰식자산에스테르, 3-갈로일-l- 에피-갈로카테콜이다. 또한 스테로이드인 테아스테롤(C29H50O), a-스피나스테롤과 트리테르페노이드인 β-아미린(C30H 48O) 팔트레우빈(C30H50O)과 카로틴 비타민 C, 쿠에르세틴, 켐페롤, 아미노산인 아르기닌, 테아닌이 있다. 차의 단맛은 주로 테아닌에 의한 것이다. 녹차에는 정유 약 0.006%가 있는데 그 주성분은 α-β-헥세놀(CH3-CH2-CH=CH-CH2-CH 2OH)(50~60%),α-β-헥세놀 (CH3-(CH2)2-CH=CH-CH2O)(5%), 이소부틸알데히드, 이소발레릴알데히드, 메틸에틸아세초알데히드, 길초산, 살리실 산메틸, 벤질 알코올, 리날로올 등이 있다. 알칼로이드로는 카페인 외에도 테오필린, 테오브로민, 크산틴, 아데닌, 히포크산틴, 파라크 산틴, 메틸크산틴, 이사틴이 있다. 또한 레시틴, 튜클레오티드아데닌, 뉴클레오티드시토신, 철과 망간이 들어 있는 뉴클레오프로테이드와 쿠마린(움벨리페론-7-글루코시드), 비타민 B1, B2, B3, B5, K(156~233mg%)가 있다. 그리고 정유, 플라보놀 배당체(쿠에르세틴과 켐페롤유도체)가 있다. 씨에는 카페인 기름 22%(씨 속에 18%) 테아사포닌(C57H90O26)이 있다. The main components of the leaves are 1-6% of purine bases such as caffeine (C 8 H 10 O 2 N 4 ), xanthine (C 5 H 4 O 2 N 4 ) and theophylline. It also has 9-15% tea tree tannins. Among them, soluble tannin is about 3% and insoluble tannin is 9.9%. Tea tree tannin (C 22 H 18 O 10 ) is a molar ester of theacatechol, 3-galloyl-l-epi-gallocatechol. In addition, steroid thetasterol (C 29 H 50 O), a-spinasterol and triterpenoids β-amirin (C 30 H 48 O) Palthreubin (C 30 H 50 O) and carotene vitamin C, Quercetin, camphorol and the amino acids arginine and theanine. The sweetness of tea is mainly due to theanine. Green tea contains about 0.006% of essential oils, the main components of which are α-β-hexenol (CH 3- CH 2- CH = CH - CH 2- CH 2 OH) (50-60%), α-β-hexenol (CH 3- (CH 2 ) 2 -CH = CH - CH 2 O) (5%), isobutylaldehyde, isovalerylaldehyde, methylethylacechoaldehyde, gilacetic acid, methyl salicylate, benzyl alcohol, linalool Etc. Alkaloids include theophylline, theobromine, xanthine, adenine, hypoxanthine, paraxanthine, methylxanthine and isatin. It also contains lecithin, nucleotide adenine, nucleotide cytosine, nucleorotate and coumarin (umbeliferone-7-glucoside) containing iron and manganese, vitamins B 1 , B 2 , B 3 , B 5 , K ( 156 ~ 233mg%). And essential oils, flavonol glycosides (quercetin and camphorol derivatives). Seeds contain 22% caffeine oil (18% in the seed) theasaponin (C 57 H 90 O 26 ).
테아사포닌은 테아사포게놀(C30H50O6),클루쿠론산(C6H10 O7), 갈락토오소, 아라비노오스, 크실로오스, 안겔리크산으로 물분해 된다. 씨에는 33%의 녹말, 8.5%의 단백질이 있다. 줄기, 뿌리, 씨에는 스테로이드사포닌이 있는데 특히 씨(9~10%)에 많다. Theasaponin is hydrolyzed to theaasapogenol (C 30 H 50 O 6 ), glucuronic acid (C 6 H 10 O 7 ), galactose, arabinose, xylose, and angelic acid. Seeds contain 33% starch and 8.5% protein. Stems, roots, and seeds contain steroid saponins, especially in seeds (9-10%).
차나무는 신경계통을 흥분시키고 정신적, 육체적 활동을 강화시키는데 써왔다. 피속에 프로트롬빈이 적은 어린이들에게 먹이면 그 함량이 높아 진다. Tea trees have been used to excite the nervous system and strengthen mental and physical activity. Feeding children with low levels of prothrombin in their blood increases their content.
찻잎: 카페인과 차나무 카데킨의 원료로 사용된다. 이 약들은 핏줄취약성이 약해지고 투과성이 파괴 될 때 출혈성 소질, 망막출혈, 광선병, 고혈압에 사용된다. 카페인은 긴장약으로 숨쉬기가 곤란한 때 심장활동이 약할 때 혈압이 낮은 일반 쇠약, 급성 전염성 질병, 정신적 육체적 피로에 사용된다. 또한 알코올 중독이나 아편 중독에 독 풀이약으로 사용된다. 테오필린은 심장의 피순환을 좋게하며 심장과 콩팥의 기능부전으로 오는 피순환 장애에 오줌내기약으로 사용된다. 테오브로민은 심장의 피순환장애, 고혈압 심장성 부종에 쓰이는 디우레틴과 테오필린, 기관지 천식과 협심증 등에 쓰이는 오이필린, 안타스티만 이라는 의약품 의 조성에 들어간다. Tea Leaves: Used as a source of caffeine and tea tree cadkin. These drugs are used for hemorrhagic predisposition, retinal bleeding, photopathy, and high blood pressure when the weakness of the blood vessels and the permeability are destroyed. Caffeine is used for tension-induced weakness in general, low blood pressure, acute infectious diseases, and mental and physical fatigue when heart activity is weak. It is also used as a poison medicine for alcoholism and opioid poisoning. Theophylline improves the blood circulation of the heart and is used as a pee medicine for blood circulation disorders that result from dysfunction of the heart and kidneys. Theobromine is used in the formulation of drugs called diuretin and theophylline, which are used for cardiovascular disorders, hypertensive cardiac edema, and opiphyline, which are used for bronchial asthma and angina.
녹차엽은 어린 잎을 따서 발효시키지 않고 즉시 말린 것이다. 향기는 약하게 나지만 생리적인 활성이 있다. 녹차는 항미생물 활성이 있기 때문에 달임약으로 하여 적리치료에 사용된다. 즉 100g 마른 녹치앞에 2L의 물을 넣고 20~30분 동안 담가두웠다가 한 시간 끓이고 이것을 두겹의 천으로 여과하고 밥먹기 20~30분 전에 1~2 스푼씩 하루 3번 복용한다. 금성 적리에는 5~10일, 만성적리에는 16~20일 먹는다. 대장염, 직장염, 소화불량에도 복용된다. 차갑게 하여 햇볕에 타는 것을 막기 위해 외출전에 노출 예상부위를 준비된 녹차우린 물로 도포한다. 또한 햇볕에 의한 화상에도 아픔과 열을 덜어준다. Green tea leaves are immediately dried without picking young leaves. The fragrance is weak but physiologically active. Since green tea has antimicrobial activity, it is used as a decoction for proper treatment. In other words, put 2L of water in front of 100g dry anchovy, soak for 20-30 minutes, boil for an hour, filter it with a double layer of cloth, and take 1 to 2 spoons 3 times a day 20 ~ 30 minutes before eating. 5-10 days for Venus Ely, 16-20 days for Chronic. It is also taken for colitis, proctitis and dyspepsia. To prevent cold and sunburn, apply the green tea with water. It also relieves soreness and heat from sunburn.
차를 음용하는 방법은 다양하다. 진한 찻물을 우유에 타서 마시기도 하며 뜨거운 물이나 사탕과 함께 마시기도 한다. 아침에 차를 마시면 사람의 활동에 필요한 여러가지 성분이 차에 많이 포함되어 있으므로 일상생활에 긍정적 영향을 준다. There are many ways to drink tea. You can drink dark tea with milk and drink it with hot water or candy. Drinking tea in the morning can have a positive effect on your daily life because it contains many different ingredients necessary for human activities.
성분(10)의 차전초(Plantago asiatica L.(P.major L. var.asiatica)는 다른 이름으로 길장구와 배부장이가 있고, 꽃필 때 잎의 밑부분을 잘라서 햇볕에 말린다. 주성분은 잎에 이리노이드 배당체인 아우쿠빈(C15H24O9), 카탈폴과 플라보노이드인 플란타기닌(스쿠텔라레인-7-글루코시드), 호모플란타기닌(히스피톨린-7글루코시드)이 있다. 플란타긴(5,6,4-트리메틸스쿠텔라레인-7-글루코시드)이 있다. 이밖에 아피게닌, 루테올린, 네페틴, 6-옥시루테올린 배당체가 있다. 잎에는 또한 우르솔산, 헨트리아콘탄(C23H48), β-시토스테롤, 스티그마스테롤 및 β-시토스테롤의 팔미트산 에스테르가 있다. 효소(에물신과 인베로틴)와 카로틴, 아스코르빈산도 있다 씨에는 아우쿠빈과 점액이 있다. 점액을 부분 물분해하면 이당류 Ⅰ〔O-β-D-크실로피라노실-(1→2)-D-크실로피라노오스〕, Ⅱ〔O-β-D-크실로피라노실-(1→4)-D-크실로피라노오스〕, Ⅲ〔(O-β-D-글루코피라노실-우론산-(1→5)-L-아라비노피라노오스〕이 생긴다. 이 밖에 플란테놀산(플란타고산), 호박산, 콜린, 아데닌, 비타민A와 B1이 있다. 전초에는 물에 풀리는 다당류가 있다. 다당류에는 회분이 28%까지 있으며 전기투석으로 50%를 제거할 수 있다. 오랜시간 정제하면 회분이 0.4~0.5%가 발생된다. 다당류는 80~82%의 펙틴산, 5~6%의 갈락토아라반 4~5%의 갈락탄으로 이루어진다.Plantago asiatica L. (P.major L. var.asiatica), under the different name, has a long janggu and a baejanggi, and cuts the bottom of the leaf when it blooms and dries it in the sun. Audine glycosides (C 15 H 24 O 9 ), catalpol and flavonoids flantaginine (scutellalane-7-glucoside), homoplantaginine (hispitolin-7 glucoside). Lantagin (5,6,4-trimethylscutellane-7-glucoside), in addition to apigenin, luteolin, nefetin, and 6-oxyluteolin glycosides, leaves also include ursolic acid and hentri Palmitic acid esters of acontane (C 23 H 48 ), β-sitosterol, stigmasterol, and β-sitosterol, as well as enzymes (emulsine and inverotene), carotene and ascorbic acid. Partial hydrolysis of mucus results in the disaccharide I [O-β-D-xyclopyranosyl- (1 → 2) -D-xyclopyranose. ], II [O-β-D- xyclopyranosyl- (1 → 4) -D- xylopyranose], III [(O-β-D-glucopyranosyl-uronic acid- (1 → 5) ) -L-arabinopyranose], as well as plantenolic acid (plantagoic acid), succinic acid, choline, adenine, vitamins A and B 1. Outpost contains polysaccharides that are released in water. Up to 28%, and 50% can be removed by electrodialysis, and long-term purification yields 0.4-0.5% ash, polysaccharides 80-82% pectinic acid, 5-6% galactoaraban 4 Consists of ~ 5% galactan.
펙틴산은 물분해 하면 갈락투론산 78~83%, 갈락토오스, 아라비노오스, 람노오스, 적은양의 포도당, 크실로오스와 이밖에 3개의 당이 생긴다. 즉 다당류는 모두 9개의 당과 무기질로 이루어져 있다. 광물질을 없앤 다당류에는 갈락투론산의 무수물이 66~68% 있다. 이것을 물분해 하면 갈락투론산이 된다. 다당류를 이루고 있는 람노오스, 아라비노오스, 갈락토오스, 크실로오스, 글루코노오스, 만노오스의 상대 함량비가 6:6:3.5:2.5:1:1이다. 갈락투론산은 주로 펙틴이다. 질경이를 유럽에서 자라는 피 메이져(P.major)와 화학분류의 입장에서 성분을 비교하면 질경이에는 이리노이드 배당체가 한가지 더 있으며, 6-옥시루테올린 배당체가 있다. When hydrolyzed, pectinic acid produces 78-83% of galacturonic acid, galactose, arabinose, rhamnose, small amounts of glucose, xylose and three other sugars. That is, the polysaccharide is composed of all nine sugars and minerals. Mineral-free polysaccharides contain 66-68% anhydrous galacturonic acid. Hydrolysis of this leads to galacturonic acid. The relative content of polysaccharides of rhamnose, arabinose, galactose, xylose, glucose and mannose is 6: 6: 3.5: 2.5: 1: 1. Galacturonic acid is mainly pectin. In comparison with P.major, which grows plantain in Europe from the standpoint of chemical classification, there is one more irinoid glycoside and 6-oxyluteolin glycoside.
다당류의 함량은 자라는 시기에 따라 8~19% 범위에서 변화한다. 봄철에 잎 이 돋아날 때부터 점차 높아져 꽃대가 나오기 시작 할 때 제일 높다. 열매가 여물고 꽃대가 마르면 그 함량이 제일 낮아진다. 원료의 생산성을 고려 한다면 꽃대가 돋아 날 때부터 꽃이 질 때까지인 6월에 채취하는 것이 좋다.The content of polysaccharides varies between 8 and 19% depending on the growing season. It is the highest when the leaves start to grow in spring and the flower beds begin to emerge. When the fruit is ripe and the flower stalk dries, its content is lowest. Considering the productivity of raw materials, it is best to collect them in June, from the time the buds sprout to the flowers.
전초와 플란타긴의 작용은 동물실험에서 호흡중추에 작용하여 호흡을 느리고 깊게 한다. 또한 점막의 분비기능을 높여 기관지점막과 소화액의 분비를 늘린다. 씨의 점액은 완화 작용과 열내린작용을 한다. 질경이의 진해 거담작용은 용혈작용과 점막에 대한 자극작용이 있는 사포닌과 다르다. 용혈작용과 부작용이 없기 때문에 어린이 기침약으로 사용된다. 질경이는 또한 오줌내기작용이 있다. 수분배설을 늘릴 뿐만아니라 요소, 염화나트륨, 요산의 배설도 촉진한다. 다당류 성분은 항 염증작용, 상피화 촉진한다. 전초에서 분리한 다당류는 독성이 적다. 다당류를 흰쥐에게 1~3g/kg, 개에게 2~5g/kg 씩 14일 동안 먹여도 독작용은 없다. 다당류는 부타디온에 의한 흰쥐의 위궤양 형성을 억제한다. 또한 개에게 먹이면 위액의 분비량을 2.5배 늘리며, 위액의 유리산도와 총 산도를 20~30% 높인다. 그러나 위액의 단백질 용해 활성에는 영향이 없다. 다당류는 위를 통하여 물질의 이동을 3~4배로 느리게 한다. 흰쥐의 떼낸 장에 대한 다당류의 진경작용은 1:10,000액에서도 나타난다. The action of outposts and planttagins acts on the respiratory center in animal experiments, slowing and deepening breathing. It also increases the secretion of mucous membranes, increasing the secretion of bronchial mucosa and digestive juices. Seed mucus acts as a relief and fever. The antitussive expectoration of plantain is different from saponin with hemolytic action and irritation to mucous membranes. It is used as a child's cough medicine because it has no hemolysis and no side effects. Plantain also has a peeing action. In addition to increasing water excretion, it also promotes excretion of urea, sodium chloride and uric acid. The polysaccharide component is anti-inflammatory, promotes epithelialization. Polysaccharides isolated from outposts are less toxic. Polysaccharides in rats 1 to 3g / kg, dogs to 2 ~ 5g / kg for 14 days, there is no poison. Polysaccharides inhibit gastric ulcer formation in rats by butadione. Feeding dogs also increases the secretion of gastric juice by 2.5 times and increases the free acidity and total acidity of gastric juice by 20-30%. However, it does not affect the protein lytic activity of gastric juice. Polysaccharides slow the movement of matter three to four times through the stomach. The hardening effect of polysaccharides on isolated intestines of rats is also shown in 1: 10,000 solution.
또한 다당류는 진경작용과 항 염증작용, 상피화 촉진작용이 있으므로 궤양에 좋은 치료약이 된다. 다당류에 있는 무기물을 갈라낸 것은 이러한 작용이 없다. 그러므로 무기물과 결합된 다당류가 생물학적 활성이 있는 성분이라고 생각된다. 다당류는 임상시험에서도 치료 효과가 있다는 것이 밝혀졌다. 위 십이지장궤양 환 자가 한번에 0.5~1g 씩 하루 3번 먹으면 5~7일 지나서 통증이 없어지고 15~20일 지나면 궤양증상이 없어지면서 위액의 산도가 정상으로 된다. 다당류의 작용상 특징은 높아진 산도를 낮추고 낮아진 산도를 높여 위액의 분비를 정상화 시키는 것이다. 특히 위액의 산도가 정상이거나 낮은 환자들에게 치료효과가 좋다.In addition, polysaccharides have antifungal, anti-inflammatory and epithelialization effects, making them a good treatment for ulcers. Splitting minerals in polysaccharides does not have this effect. Therefore, it is considered that the polysaccharide combined with the inorganic material is a biologically active component. Polysaccharides have been shown to be therapeutic in clinical trials. Gastric duodenal ulcer patients with 0.5 ~ 1g at a time three times a day, 5 to 7 days after the pain disappears, 15 to 20 days after the ulcer symptoms disappear, the acidity of the gastric juice is normal. The functional feature of polysaccharides is to lower the acidity and increase the acidity to normalize the secretion of gastric juice. In particular, patients with normal or low acidity of gastric juice have good therapeutic effect.
응용하는 곳은 전초에서 얻은 다당류 또는 생즙은 위액의 산도가 정상이거나 낮은 십이지장궤양과 만성 위염에 사용된다. 전초 달임 약은 신석증에도 효과가 있다. 동의 치료에서는 전초를 위병과 기타 동맥경화, 당뇨병에 사용된다. 씨는 눈병, 신경계통 질병에 달여 마신다.Applications include polysaccharides or juices derived from outposts used for duodenal ulcers and chronic gastritis with or without acidity in gastric juice. Outpost decoction is also effective for nephropathy. In copper therapy, outposts are used for gastrointestinal and other arteriosclerosis and diabetes. Mr. Moon drinks from eye diseases and nervous system diseases.
본 발명에 따른 흡연으로 인한 유해성분 제거용 생약추출물의 제조방법이 제1실시예를 하기에서 보다 상세히 각각의 단계별로 설명한다.Method for producing a herbal extract for removing harmful components due to smoking according to the present invention will be described in each step in more detail below in the first embodiment.
제1단계는 알로에, 금잔화, 까마중, 삼칠, 녹차엽, 약모밀, 새삼덩굴, 인동덩굴, 감초 및 차전초를 각각 건조하여 건조물을 형성하는 단계이며, 상기 열거된 재료의 건조는 햇빛이 없는 그늘에서 수행한다. 양지에서 건조 시키면, 함유된 유효성분들이 파괴되거나 증발함으로 인하여, 약효가 저하되거나 추출물의 양이 감소하게 된다. 건조는 재료표면의 수분이 거의 증발된 상태까지 행하고, 예를들어 풀잎의 경우 끝부분이 약간씩 말려있을 정도가 될 때까지 건조 시키는 것이 바람직하다. 건조과정을 거친 재료에 투입되는 용매의 량이 건조된 재료의 무게에 따라 다르게 되고 또 건조가 적당히 된 것일수록 용매의 사용량을 줄일 수 있으므로 각 건조물의 건조 공정을 적정하게 행하는 것이 바람직하다.The first step is a step of drying the aloe, marigold, camellia, samchil, green tea leaf, weak buckwheat, bird vine, honeysuckle, licorice and chajeoncho, respectively, to form a dry matter, the drying of the materials listed above is carried out in the shade without sunlight do. When dried in the sun, due to the destruction or evaporation of the active ingredients contained, the drug is reduced or the amount of extract is reduced. Drying is carried out until the moisture on the surface of the material is almost evaporated. For example, it is preferable to dry the blade until the tip is slightly dried. Since the amount of the solvent added to the dried material varies depending on the weight of the dried material and the drying amount is appropriate, the amount of the solvent can be reduced, so it is preferable to appropriately perform the drying step of each dried product.
제2단계는 상기 제1단계의 각 건조물에 용매를 넣고 가열하여 건조물의 성분 이 용매에 추출되어 추출용액을 형성하는 단계이다. 건조된 각각의 재료에 투입되는 용매의 양은 건조물 100g 당 용매를 약 1.5 ~ 2.5L 혼합한다.In the second step, a solvent is added to each of the dried products of the first step, and the components of the dried products are extracted into the solvent to form an extraction solution. The amount of solvent added to each dried material is mixed about 1.5 to 2.5 L of solvent per 100 g of dry matter.
제2단계의 상기 용매는 물, 저급 알코올류, 에스테르류, 케톤류, 지방족 탄화수소류 및 클로로포름으로 이루어진 군으로부터 선택된 하나 이상인 것이며, 바람직하게는 물, 에탄올, 메탄올, 이소프로필 알코올, n-부탄올을 포함하는 저급 알코올류, 초산에틸을 포함하는 에스테르류, cyclo-부탄올을 포함하는 케톤류, cyclo-펜탄, n-헥산, 클로로포름 및 아세톤 중에서 선택된 적어도 하나 이상으로 이루어 진다. 제2단계의 상기 용매는 극성도가 클수록 많은 추출용액을 얻을 수 있다. 또한 상기 제1단계의 각각의 건조물의 산지나 채집 시기에 따라 추출용액의 양 에 있어서 차이가 있다.The solvent of the second step is at least one selected from the group consisting of water, lower alcohols, esters, ketones, aliphatic hydrocarbons and chloroform, preferably water, ethanol, methanol, isopropyl alcohol, n-butanol It consists of at least one selected from lower alcohols, esters containing ethyl acetate, ketones containing cyclo-butanol, cyclo-pentane, n-hexane, chloroform and acetone. The greater the polarity of the solvent of the second step, the more extraction solution can be obtained. In addition, there is a difference in the amount of the extraction solution according to the production site or the collection time of each dry matter of the first step.
상기 열거된 용매중 선택된 용매가 혼합된 각각의 건조물을 가열하는 방법은 환류 냉각기가 설치된 맨틀을 이용하여 대기압 조건으로 약 1-5시간동안 가열한다.기압을 대기압 이하로 낮추면 가열시간을 단축할 수 있으므로 필요한 경우에 기압을 0.1기압 이하로 낮추어 가열시간을 대폭 단축 시킬 수도 있다. 가열온도는 사용되는 용매의 비등점을 고려하여 적절히 조정하면 된다. 대체적으로 대기압 하에서는 1-5시간 정도 가열하면 건조물로부터 추출성분이 용해되며, 필요에 따라서 가열시간을 줄이거나 연장 할 수 있다.In the method of heating each dried material selected from the above-listed solvents, heating is performed for about 1-5 hours under atmospheric pressure using a mantle provided with a reflux condenser. By lowering the atmospheric pressure below atmospheric pressure, the heating time can be shortened. Therefore, if necessary, the air pressure can be lowered to 0.1 atm or less, which greatly shortens the heating time. What is necessary is just to adjust heating temperature suitably in consideration of the boiling point of the solvent used. In general, heating at atmospheric pressure for 1-5 hours dissolves the extract components from the dry matter and may reduce or extend the heating time as necessary.
제3단계는 상기 제2단계의 추출용액을 여과하여 고형물질을 제거하는 단계이다. 상기 제2단계를 걸친 상기 추출용액은 건조물과 용매가 섞여져 있는 액상 상태로 존재하게 되는데, 상기 추출용액 내의 찌꺼기 상태의 건조물을 여과기에서 여과 시켜 건조물의 성분이 녹아있는 여과된 추출용액을 얻는다.The third step is to remove the solid material by filtering the extraction solution of the second step. The extraction solution passed through the second step is present in a liquid state in which the dry matter and the solvent are mixed, and the filtered dry solution of the dried state in the extract solution is filtered by a filter to obtain a filtered extract solution in which the dry matter is dissolved.
제4단계는 상기 제3단계의 여과된 추출용액에 함유된 용매성분을 증발시켜 각각의 추출물을 얻는 단계로 0.005 내지 0.1 기압에서 40 내지 60℃의 온도로 가열시키는 단계이다. 여기에서 증발온도를 섭씨 60℃ 이상으로 높게하면, 추출용액에 화학 변화가 발생하거나 감압시 추출용액의 성분이 빠져 나갈 우려가 있고, 온도를 섭씨 40℃ 이하로 하는 경우에는 증발에 과도한 시간이 소요된다.The fourth step is to obtain each extract by evaporating the solvent component contained in the filtered extraction solution of the third step is a step of heating to a temperature of 40 to 60 ℃ at 0.005 to 0.1 atm. If the evaporation temperature is increased to 60 ° C or higher, there may be a chemical change in the extraction solution or the components of the extraction solution may come out when depressurizing, and when the temperature is 40 ° C or lower, excessive time is required for evaporation. do.
제 5단계는 상기 제4단계의 추출용액으로부터 분리된 추출물을 소정의 비율로 혼합하여 혼합추출물을 제공하는 단계이다. The fifth step is to provide a mixed extract by mixing the extract separated from the extraction solution of the fourth step in a predetermined ratio.
즉, 제 4단계로 부터 얻어진 각각의 추출물은 알로에 0.5~10 중량%, 금잔화 5~40 중량%, 까마중 5~20 중량%, 삼칠 0.5~10 중량%, 녹차엽 5~20 중량%, 차전초 5~40 중량%, 약모밀 5~40 중량%, 새삼 5~20 중량%, 감초 0.5~10 중량%의 혼합비율로 혼합하는 것이 바람직하다.That is, each extract obtained from the fourth step is 0.5 to 10% by weight of aloe, 5 to 40% by weight of marigold, 5 to 20% by weight of yam, samil 0.5 to 10% by weight, green tea leaf 5 to 20% by weight, chajeoncho 5 It is preferable to mix at a mixing ratio of -40 wt%, weak hair 5-40 wt%, fresh ginseng 5-20 wt%, licorice 0.5-10 wt%.
다음으로 제5단계에서 생성된 혼합추출물은 첨가 대상체로서 통상의 식품에 혼합추출물을 5 내지 70중량% 함유시켜 기능성 식품으로 제조한다. Next, the mixed extract produced in the fifth step is prepared as a functional food by containing 5 to 70% by weight of the mixed extract in a conventional food as an additive object.
식품에 함유되는 혼합추출물의 양이 5% 미만이면 유해성분의 제거 효과가 미비 하고, 혼합추출물의 양이 5% 이상 첨가되면 유해성분의 제거 효과가 현저히 나타나게 되므로 혼합추출물의 첨가량은 5 내지 70중량% 함유시키는 것이 바람직하다.When the amount of the mixed extract contained in the food is less than 5%, the removal effect of the harmful component is insufficient, and when the amount of the mixed extract is added 5% or more, the removal effect of the harmful component is remarkable. It is preferable to make it contain%.
또한 상기 혼합추출물을 첨가할 수 있는 기능성 식품으로서, 요구르트, 캔디, 쿠키, 젤리, 츄잉껌등의 과자류, 청량 음료수 등이 있고, 담배 첨가물 형태 로도 적용할 수 있다. 또한 의약, 한방약 등에 배합되는 원료로도 첨가할 수 있다.In addition, as a functional food to which the mixed extract can be added, there are confectionery such as yogurt, candy, cookies, jelly, chewing gum, soft drinks, etc., and can also be applied in the form of tobacco additives. Moreover, it can also add as a raw material mix | blended with medicine, herbal medicine, etc.
또 제5단계에서 제조된 혼합추출물은 부형제인 유당, 옥수수 전분, 미세 결정질 구조의 셀룰로오스, 마그네슘 스테아레이트 등과 혼합하여 분말, 과립, 정제, 캡슐 등의 형태로 제제화 할 수 있다.In addition, the mixed extract prepared in the fifth step may be formulated in the form of powder, granules, tablets, capsules and the like by mixing with excipients lactose, corn starch, cellulose, magnesium stearate having a fine crystalline structure.
본 발명의 흡연으로 인한 유해성분 제거용 생약추출물의 제조방법의 제2실시예는 알로에, 금잔화, 까마중, 삼칠, 녹차엽, 약모밀, 새삼덩굴, 인동덩굴, 감초 및 차전초를 각각 건조하여 건조물을 형성하는 제1단계와, 상기 제1단계의 건조물을 소정의 비율로 혼합하여 혼합 건조물을 제공하는 제2단계와, 상기 제2단계의 혼합 건조물에 수용성 용매를 넣고 가열하여 건조물의 성분이 용매에 추출된 혼합 추출용액을 형성하는 제3단계와, 상기 제3단계의 혼합 추출용액을 여과하여 고형물질을 제거하는 제4단계와, 상기 제4단계에서 여과된 혼합 추출용액에 함유된 용매성분을 증발시켜 혼합추출물을 제공하는 제5단계로 이루어진다.The second embodiment of the manufacturing method of the herbal extract for the removal of harmful components due to smoking of the present invention is dried aloe, marigold, black yam, samchil, green tea leaf, weak wheat, bird vine, honeysuckle, licorice and tea vinegar respectively to form a dried product The first step, and the second step of mixing the dry matter of the first step in a predetermined ratio to provide a mixed dry matter, the water-soluble solvent is added to the mixed dry matter of the second step and heated to extract the components of the dry matter to the solvent A third step of forming a mixed extract solution, a fourth step of filtering the mixed extract solution of the third step to remove solids, and a solvent component contained in the mixed extract solution filtered in the fourth step The fifth step is to provide a mixed extract.
본 실시예에서는 각 재료의 건조물을 소정의 비율로 미리 혼합한 후 추출용액을 형성하고, 여과 및 증발하는 공정으로 이루어지는 점을 제외하고는 제1실시예와 동일하므로, 이에 대한 상세한 설명은 생략한다.This embodiment is the same as in the first embodiment except that the dried solution of each material is pre-mixed in a predetermined ratio to form an extraction solution, followed by filtration and evaporation, and thus a detailed description thereof will be omitted. .
본 실시예의 제2단계의 건조물의 혼합 비율은 알로에 0.5~10 중량%, 금잔화 5~40 중량%, 까마중 5~20 중량%, 삼칠 0.5~10 중량%, 녹차엽 5~20 중량%, 차전초 5~40 중량%, 약모밀 5~40 중량%, 새삼덩굴 5~20 중량%, 인동덩굴 5~30 중량%, 감초 0.5~10 중량%의 비율의 범위 내로 각각의 혼합건조물을 형성하는 것이 바람직하다. The mixing ratio of the dried product of the second step of the present embodiment is 0.5 to 10% by weight, marigold 5 to 40% by weight, 5 to 20% by weight in yam, samil 0.5 to 10% by weight, green tea leaves 5 to 20% by weight, chajeoncho 5 It is preferable to form the respective mixed dry matter in the range of the ratio of -40 wt%, weak hair 5-40 wt%, bird vine 5-20 wt%, honeysuckle 5-30 wt%, licorice 0.5-10 wt%.
본 발명에 따른 생약추출물의 제조방법에서 사용되는 다양한 용매에 따른 생 약추출물의 수율을 비교하는 실험을 수행하였다.Experiments were performed to compare the yields of the herbal extracts according to the various solvents used in the preparation method of the herbal extracts according to the present invention.
① 실험 방법① Experiment Method
상기 건조물 및 추출물 100g당 용매를 2L씩을 첨가하여 실험을 수행하였고, 상기 건조물및 추출물과 용매를 환류냉각기가 설치된 맨틀에서 대기압하에 2시간동안 가열하고, 가열된 혼합물의 상부에 있는 찌꺼기를 제거하고, 하부에 있는 액상의 잔존물을 여과하고 상기 건조물로부터 얻어지는 각각의 추출물과 상기 추출물으로부터 얻어지는 혼합추출물을 수득물로 얻었다.The experiment was performed by adding 2 L of solvent per 100 g of the dried substance and the extract, and the dried substance and the extract and the solvent were heated under atmospheric pressure for 2 hours in a mantle provided with a reflux condenser, and the residue on top of the heated mixture was removed. The liquid residue in the lower part was filtered and each extract obtained from the dried product and the mixed extract obtained from the extract were obtained as the obtained product.
상기 각각의 추출물과 혼합추출물을 0.008기압(5mmHg) 및 섭씨 50℃의 조건하에서 용매를 증발시켜 최종적으로 각각의 건조 추출물과 혼합형태의 건조추출물을 얻는다. The respective extracts and mixed extracts were evaporated under a condition of 0.008 atm (5 mmHg) and 50 ° C. to finally obtain dry extracts and mixed extracts of each dry extract.
② 실험결과② Experiment Result
용매의 종류별로 얻어지는 건조 추출물 및 혼합형태의 건조 추출물의 양은 물과 에탄올, 메탄올을 용매로 첨가하여 제조하는 경우에 수득률이 높게 나타났으며, 인체에 해가 없는 점을 고려 할 때 바람직한 용매로는 물과 에탄올을 용매로 사용하는 것이 효과적이다. The amount of the dry extract and the dry extract of the mixed form obtained by each type of solvent was high in yield when water, ethanol and methanol were added as a solvent. It is effective to use water and ethanol as solvents.
표 1은 용매의 종류별로 얻어지는 수율 값을 나타내었다.Table 1 shows the yield values obtained for each type of solvent.
[표 1]TABLE 1
표1의 결과로부터 확인된 물과 에탄올을 적용하여 제조된 생약추출물의 작용효과를 설명하기 위하여 행해진 실험 및 그 결과를 상세히 하기에 설명한다. Experiments performed to explain the effect of the herbal extract prepared by applying water and ethanol confirmed from the results of Table 1 and the results are described in detail below.
가. 혈액중 니코틴 농도 측정 실험 end. Test of nicotine concentration in blood
1. 실험 조건1. Experimental conditions
① 시험동물① Test Animal
위스터 스트레인(Wister strain)수컷 랫트(6주령)의 아이씨알 쥐(ICR Mouse) ICR Mouse of Wister strain male rats (6 weeks old)
② 시험환경② Test environment
동물을 실온 24±℃, 습도 55±5%, 환기회수 12회/시간, 조명시간 12시간/일(아침 8시 점등, 밤 8시 소등)로 설정된 동물실의 철망 사육실에 5마리씩 수용 하였다. 사료는 고체사료를 물과 함께 자유롭게 섭취하도록 하였다. Five animals were housed in a wire cage in an animal room set at room temperature 24 ± ° C., humidity 55 ± 5%, ventilation number 12 times / hour, lighting time 12 hours / day (light at 8 am, light at 8 am). The feed was made free of solid feed with water.
③ 투여방법③ Method of administration
시험환경에 2주간 적응시키고, 8주령에서 동물을 시험하였다. 시험물질은 실시예로부터 얻어진 생약추출물을 고체사료에 섞어서 경구 투여하였다. 실시예로 부터 얻어진 생약추출물을 0.5ml/마리 고체사료에 섞어서 물과 함께 자유롭게 먹이로서 체내에 경구 투여하였다. Adapted to the test environment for 2 weeks, animals were tested at 8 weeks of age. The test substance was orally administered by mixing the herbal extract obtained in Example with a solid feed. The herbal extracts obtained from the examples were mixed in 0.5ml / mari solid feed and orally administered to the body as free food with water.
④ 투여시간 ④ Dosing time
투여는 오후 2시에 실시하고, 기간은 7일간으로 하였다. 투여 종료시 및 시험 종료시에 니코틴 측정을 위한 시료로 심장으로부터 1ml 채혈하였다. Administration was performed at 2 pm and the period was 7 days. At the end of dosing and at the end of the test, 1 ml of blood was drawn from the heart as a sample for nicotine measurement.
⑤ 관찰방법⑤ Observation method
투여일은 투여직후와 저녁에, 그 다음날부터는 아침과 저녁에 관찰하였다. 관찰은 동물을 사육자 바깥으로부터 주의 깊게 실시하였다.Dosing days were observed immediately after administration and in the evening, and the morning and evening thereafter. Observation was carefully conducted from outside the breeder.
2. 실험결과2. Experimental Results
① 혈액중 니코틴 농도① nicotine concentration in blood
혈액을 묽은 암모니아수로 pH 9로 조절하였다. 다음과정으로 익스터넛 칼럼(EXTRELUT COLUMN;Merck사 제품)에 15분간 유지시키고, 15ml의 에틸 아세테이트로 용출하고, 용출된 아세테이트를 감압하에 증류 제거하고, 생성된 잔사에 100㎕의 에틸 아세테이트를 가하여 용해시키고 분석시료로 하였다.Blood was adjusted to pH 9 with dilute ammonia water. Next, the resultant was maintained on an outer column (EXTRELUT COLUMN; manufactured by Merck Co., Ltd.) for 15 minutes, eluted with 15 ml of ethyl acetate, the eluted acetate was distilled off under reduced pressure, and 100 µl of ethyl acetate was added to the resulting residue. The sample was analyzed.
분석은 가스크로마토그래피(미국 HP사 5890 SERIESП, FID부착)사용 칼럼은 2% 써몬(Tharmon)1000+1% 수산화칼륨(KOH) 크로모소브 더블류에이엠(Chromosorb WAM;8/100Mesh)를 충전한 길이 2m, 직경 3mm의 유리 칼럼을 사용하였다.The analysis was performed using gas chromatography (HP 5890 SERIESП, FID, USA) with 2% Tharmon 1000 + 1% KOH chromosorb WAM (8 / 100Mesh). A glass column 2 m long and 3 mm in diameter was used.
칼럼온도는 100℃, 캐리어 기체는 질소(N2)를 사용하였고 유속은 60ml/분으로 하였다. 표 2에 실시예로 부터 얻어진 생약추출물을 7일동안 투여한 결과를 나타내었으며, 니코틴 농도는 30mg/kg/10ml이고 복강 투여하였다.The column temperature was 100 ° C., the carrier gas used nitrogen (N 2 ), and the flow rate was 60 ml / min. Table 2 shows the result of administering the herbal extract obtained from the example for 7 days, and the nicotine concentration was 30 mg / kg / 10ml and was intraperitoneally administered.
[표 2]TABLE 2
참고사항 - G1 : 실시예로 부터 얻어진 생약추출물을 전처리 후 니코틴 투여.Note-G1: Nicotine administration after pretreatment of the herbal extract obtained in Example.
G2 : 실시예로 부터 얻어진 생약추출물을 전처리 후 니코틴 투여후 실시예로 부터 얻어진 생약추출물을 투여.G2: After pretreatment of the herbal extracts obtained from the examples, administration of the herbal extracts obtained from the examples after nicotine administration.
G3 : 대조군 니코틴 투여. G3: control nicotine administration.
G4 : 대조군 니코틴 투여후 실시예로 부터 얻어진 생약추출물을 투여.G4: Administration of the herbal extract obtained from the Example after administration of the control nicotine.
시험 개체수는 각 군별로 다섯 마리씩 시험하였다 The test population was tested five dogs in each group
② 부검② autopsy
투여 종료시의 부검에서 회복된 경우 각 개체에서 육안적 이상은 발견되지 않았으나 사망한 경우 각 개체에서 육안적 이상이 발견되었다.At the end of dosing, there was no gross abnormality in each individual when recovered from necropsy, but gross abnormalities were found in each individual at death.
나. 뇨중 니코틴 농도의 측정실험I. Measurement experiment of urine nicotine concentration
뇨중 니코틴 농도의 측정은 실험 1의 시험동물, 시험환경, 투여방법, 투여시간, 관찰방법, 분석방법은 동일하게 실시되었으며, 뇨중의 니코틴 농도의 측정시험 결과는 하기에 설명한다.The urine nicotine concentration was measured in the same manner as the test animal, test environment, administration method, administration time, observation method, and analysis method of Experiment 1, and the results of the measurement test of nicotine concentration in urine are described below.
뇨중의 니코틴 농도의 측정시험결과는 뇨를 묽은 암모니아수를 첨가하여 pH 9로 조절하고 엑스터넛 칼럼(EXTRELUT COLUMN;Merck사 제품)에 1분간 유지시키고 15ml의 에틸 아세테이트로 용출한 다음, 용출 아세테이트를 감압하에 증류 제거하였다. 생성된 잔사에 100㎕의 에틸 아세테이트를 가하여 용해시키고 분석시료로 하였다. 표 3은 본 실시예에 따라 제조된 생약추출물을 7일동안 투여한 후의 결과이며, 니코틴 농도 30mg/kg/10ml 복강 투여하였다.Test result of nicotine concentration in urine was adjusted to pH 9 by adding dilute ammonia water to urine, maintained for 1 minute in an EXTERELUT COLUMN (manufactured by Merck), eluted with 15 ml of ethyl acetate, and then eluting acetate was Distilled off. 100 µl of ethyl acetate was added to the resulting residue to dissolve and used as an analytical sample. Table 3 shows the results after administration of the herbal extract prepared according to this example for 7 days, and was administered nicotine concentration 30mg / kg / 10ml intraperitoneally.
[표 3]TABLE 3
다. 혈액중 일산화탄소 농도 실험 All. Carbon monoxide concentration test in blood
1. 실험조건1. Experimental conditions
① 시험동물① Test Animal
위스터 스트레인(Wister strain)수컷 랫트(6주령)의 아이시알 쥐(ICR Mouse)ISTER Mouse of Wister strain male rats (6 weeks old)
② 시험환경② Test environment
동물을 실온 24±1℃, 습도 55±5%, 환기회수 12회/시간, 조명시간 12시간/일(아침 8시 점등, 밤 8시 소등)로 설정된 동물실의 철망 사육실에 5마리씩 수용하였다. 사료는 고체사료를 물과 함께 자유롭게 섭취하였다.Five animals were housed in a wire cage in an animal room set at room temperature 24 ± 1 ° C., humidity 55 ± 5%, ventilation number 12 times / hour, lighting time 12 hours / day (lighting up at 8 am, turning off at 8 pm). . Feed was freely fed solid feed with water.
③ 투여방법③ Method of administration
시험환경에 2주간 적응시키고, 8주령에서 동물을 시험하였다. 시험물질은 실시예로 부터 얻어진 생약추출물을 고체사료에 섞어서 경구 투여하였다. 실시예로 부터 얻어진 생약추출물을 0.5ml/마리 고체사료에 섞어서 물과 함께 자유롭게 먹이로 체내에 경구 투여하였다. Adapted to the test environment for 2 weeks, animals were tested at 8 weeks of age. The test substance was orally administered by mixing the herbal extract obtained in Example with a solid feed. The herbal extracts obtained from the examples were mixed in 0.5ml / mari solid feed and orally administered to the body freely with water.
④ 일산화탄소(C0) 폭로 방법④ How to expose carbon monoxide (C0)
투여 종료 다음날, 폭로용 챔버(Sugiyamage사 제품)내에 각 동물을 수용하고, O2 21%, CO 100ppm의 혼합기체를 펌프로 도입하여 5분간 흡입시켰다. 챔버내의 농도는 일산화탄소 측정기(COM-4, 일본국 Komei Rikagaku Kogyo사 제품)로서 검사하였다.On the day after the end of the administration, each animal was housed in an exposure chamber (Sugiyamage Co., Ltd.), and a mixed gas of 21% O 2 and 100 ppm CO was introduced into the pump and inhaled for 5 minutes. The concentration in the chamber was examined with a carbon monoxide meter (COM-4, manufactured by Komei Rikagaku Kogyo, Japan).
⑤ 혈액중 일산화탄소-헤모글로빈(CO - Hb) 농도의 측정⑤ Measurement of carbon monoxide-hemoglobin (CO-Hb) concentration in blood
폭로종료후 즉시 심장으로부터 채혈하여 혈액 0.5ml을 5ml 용량의 반응 유리병(reaction vial)에 넣고 옥틸알콜 한방울과 포타슘 페리시아네이트 포화 수용액 0.25ml를 가하였다 반응액을 마개로 막고 5분간 진탕한 후 기상 분석 시료로 사용하였다.Immediately after the end of the exposure, blood was drawn from the heart, 0.5 ml of blood was placed in a 5 ml reaction vial, and a drop of octyl alcohol and 0.25 ml of saturated aqueous potassium ferricyanate solution were added. It was used as a sample for gas phase analysis.
분석은 가스크로마토그래피(미국 HP사 5890 SERIESП, TCD부착)사용하고 칼럼은 분자체 5A(3/60Mesh)를 충전한 길이 2m, 직경 3mm의 유리 칼럼을 사용하였다. 칼럼온도는 60℃, 캐리어 기체는 수소(H2)를 사용하였고, 유속은 50ml/분으로 하였다.For analysis, gas chromatography (US 5890 SERIESП, TCD attached) was used, and a column of 2 m in length and 3 mm in diameter filled with molecular sieve 5A (3 / 60Mesh) was used. The column temperature was 60 ° C., the carrier gas used hydrogen (H 2 ), and the flow rate was 50 ml / min.
2. 실험결과2. Experimental Results
① 혈액중 일산화탄소의 농도① the concentration of carbon monoxide in the blood
시험후 혈액중 일산화탄소(CO)의 농도를 측정한 결과는 표 4를 참조하고, 표4는 본 실시예에 따라 제조된 생약추출물을 7일동안 투여한 결과이다. The results of measuring the concentration of carbon monoxide (CO) in the blood after the test, see Table 4, Table 4 is the result of administration of the herbal extract prepared according to the present embodiment for 7 days.
[표 4] TABLE 4
② 부검② autopsy
투여 종료시의 부검에서 각군의 경우 각 개체에서 육안적 이상은 발견되지 않았다. At the end of the autopsy, no gross abnormalities were found in each individual in each group.
라. 타(Tar)에 대한 시험la. Test for Tar
1. 실험조건1. Experimental conditions
① 시험동물① Test Animal
위스터 스트레인(Wister strain)수컷 랫트(6주령)의 아이시알 쥐(ICR Mouse)ISTER Mouse of Wister strain male rats (6 weeks old)
② 시험환경② Test environment
동물을 실온 24±1℃, 습도 55±5%, 환기회수 12회/시간, 조명시간 12시간/일(아침 8시 점등, 밤 8시 소등)로 설정된 동물실의 철망 사육실에 5마리씩 수용하였다. 사료는 고체사료를 물과 함께 자유롭게 섭취하였다.Five animals were housed in a wire cage in an animal room set at room temperature 24 ± 1 ° C., humidity 55 ± 5%, ventilation number 12 times / hour, lighting time 12 hours / day (lighting up at 8 am, turning off at 8 pm). . Feed was freely fed solid feed with water.
③ 투여방법③ Method of administration
시험환경에 2주간 적응시키고 8주령에서 동물을 시험하였다. 시험물질은 실시예로 부터 얻어진 생약추출물을 고체사료에 섞어서 경구 투여하였다. 실시예로 부터 얻어진 생약추출물을 0.5ml/마리 고체사료에 섞어서 물과 함께 자유로 먹이로서 체내에 경구 투여하였다. 타(Tar)는 위튜브(Stomach tube)를 사용하여 위 내부로 투여하였다.Adapted to the test environment for 2 weeks and animals were tested at 8 weeks of age. The test substance was orally administered by mixing the herbal extract obtained in Example with a solid feed. The herbal extracts obtained from the examples were mixed in 0.5ml / marion solid feed and orally administered to the body as free food with water. Tar was administered into the stomach using a Stomach tube.
④ 관찰방법④ Observation Method
투여일은 투여직후와 저녁에, 다음날부터는 아침과 저녁에 관찰하였다. 관찰은 동물을 사육자 바깥으로부터 주의깊게 실시하였다.Dosing days were observed immediately after administration and in the evening and morning and evening from the following day. Observation was carefully conducted from outside the breeder.
2. 실험결과2. Experimental Results
실험후 타(Tar)를 측정한 결과는 표 5에 나타내었으며, 표 5는 본 실시예에 따라 제조된 생약추출물을 투여후의 결과이다. 타(Tar)의 농도 30mg/kg/10ml 복강 투여하였다.The result of measuring the Tar after the experiment is shown in Table 5, and Table 5 is the result after administration of the herbal extract prepared according to the present Example. The concentration of Tar was administered intraperitoneally at 30 mg / kg / 10 ml.
[표 5]TABLE 5
참고사항 : G1 : 실시예로 부터 얻어진 생약추출물을 일반사료에 섞어서 전처리 후 타(Tar) 투여.References: G1: Pre-treatment by mixing the herbal extracts obtained from the example into a general feed and then administering Tar.
G2 : 대조군 일반사료를 투여하면서 타(Tar) 투여.G2: Tar administration while the control normal feed.
시험 개체수는 각 군별로 다섯 마리씩 시험하였다 The test population was tested five dogs in each group
마. 항산화력에 대한 시험hemp. Antioxidant Test
1. 시험방법1. Test Method
항산화력 실험은 기하루(Kiharu)의 방법에 따라 증류수 1㎖에 리노레익 에시드(Linoleic acid) 2mg을 첨가한 용액과 증류수 1㎖에 Tween-20 10mg을 첨가한 용액과 1시간동안 폭기 시킨 0.2M 포타슘 포스페이트(Potassium phosphate;pH 7.4) 1.0㎖에 실시예로 부터 얻어진 생약추출물을 첨가하여 혼합물을 제조하였다. 혼합물을 37℃에서 24시간동안 반응시키면서, 3시간 간격으로 반응액 0.1㎖을 취해 75% 에탄올(Etanol)을 9.7㎖을 첨가하고, 30% 암모니움 티오시안네이트(Ammonium thiocyanate) 0.1㎖와 0.02M 페로우스 암모늄 설페이트(ferrous ammonium sulfate) 3.5%, 하이드로클로릭 산(hydrochloric acid) 0.1㎖을 첨가하고 3분 후 500nm에서 흡광도를 측정하였다.Antioxidant activity was tested by the method of Kiharu, adding 2mg of linoleic acid to 1ml of distilled water, 10mg of Tween-20 to 1ml of distilled water, and 0.2M aerated for 1 hour. 1.0 ml of potassium phosphate (pH 7.4) was added to the crude herb extract obtained from Example to prepare a mixture. The mixture was reacted at 37 ° C. for 24 hours, taking 0.1 ml of the reaction solution at 3 hour intervals, adding 9.7 ml of 75% ethanol, 0.1 ml of 30% Ammonium thiocyanate and 0.02 M 3.5% of ferrous ammonium sulfate and 0.1 ml of hydrochloric acid were added and the absorbance was measured at 500 nm after 3 minutes.
2. 결과2. Results
실시예로 부터 얻어진 생약추출물의 항산화력 측정 결과는 표 6과 표 7에 나타났으며, 대조군으로는 합성 항산화제인 비에이치티(BHT;dibutyl hydroxy toluen)와 천연 항산화제인 알파토코페놀(α-Tocopherol)를 사용하였다. The antioxidant power measurement results of the herbal extracts obtained from the examples are shown in Table 6 and Table 7. As a control, the synthetic antioxidant BHT (dibutyl hydroxy toluen) and the natural antioxidant alpha-tocopherol (α-Tocopherol) Was used.
표 7은 항산화력을 측정한 측정결과이고, 표 6은 표 7로부터 측정된 항산화력의 평균값을 정리한 결과이다. 표 6에서 보듯이 실시예로 부터 얻어진 생약추출물의 경우 알파토고페놀(α-tocopherol) 보다 높은 항산화력을 나타냈으며, 비에이치티(BHT) 보단 약간 낮은 것으로 확인되었다. 또한 실시예로 부터 얻어진 생약추출물을 사용하여 항산화력을 측정해 본 결과 대조군(control)과 높은 차이를 보였음을 알 수 있었다.Table 7 shows the measurement results of the antioxidant power, and Table 6 summarizes the average values of the antioxidant powers measured from Table 7. As shown in Table 6, the herbal extracts obtained from the examples showed higher antioxidant power than alpha-tocopherol and were slightly lower than BHT. In addition, as a result of measuring the antioxidant power using the herbal extract obtained from the Example was found to show a high difference with the control (control).
[표 6]TABLE 6
[표 7]TABLE 7
바. 혈장(Plasma) 분석 실험bar. Plasma Assay
혈장은 총콜레스테롤측정, 혈중지방측정, 지질과산화 함량측정으로 수행 하였다. 3주령의 SD-rat을 보통(Normal), 니코틴, 니코틴 + 생약추출물(n=7)의 그룹으로 나누어 사육후 7주령에 희생시켰다. Plasma was measured by total cholesterol measurement, blood fat measurement, lipid peroxidation content measurement. Three-week-old SD-rat was divided into groups of normal, nicotine and nicotine plus herbal extracts (n = 7) and sacrificed at 7 weeks of age.
보통(Normal)(n=6): 자유식이. Normal (n = 6): Free expression.
니코틴(n=8):니코틴(Nicotin) 4mg/kgBW 경구투여+200mg/kgBW 생리식염수 복강투여. Nicotine (n = 8): Nicotine 4 mg / kg BW oral administration + 200 mg / kg BW physiological saline intraperitoneal administration.
니코틴+생약추출물(n=7):니코틴 4mg/kgBW 경구투여+200mg/kgBW 실시예로 부터 얻어진 생약추출물을 복강투여. Nicotine + herbal extract (n = 7): Nicotine 4 mg / kg BW oral administration + 200 mg / kg BW The herbal extract obtained from the Example is intraperitoneally administered.
1. 혈장(Plasma) 분석 1. Plasma Analysis
희생시킨 동물의 동맥에서 혈액을 채취하여 응고 방지를 위해 이디티에이(EDTA) 처리 하였다. 채취된 혈액은 3,000 rpm에 10분간 원심분리하여 혈청을 분리한 후 분석할 때까지 -70℃에서 보관하였다. Blood was collected from the arteries of the sacrificed animals and treated with EDTA to prevent coagulation. Collected blood was centrifuged at 3,000 rpm for 10 minutes to separate serum and stored at -70 ℃ until analysis.
1) 총 콜레스테롤(Total Cholesterol): 혈중 총콜레스테롤 측정 키트(Wako, Japan) 를 사용하여 유브이 흡광광도계(UV-VIS Spectrophotometer)의 505nm에서 흡광도를 측정하여 정량 하였다. 1) Total Cholesterol: Total absorbance was measured by measuring the absorbance at 505 nm of UV-VIS Spectrophotometer using blood total cholesterol measurement kit (Wako, Japan).
2) 트리글리세리드(Triglyceride): 혈중 중성지방 측정 키트(Wako, Japan)를 사용하여 유브이 흡광광도계(UV-VIS Spectrophotometer) 410nm에서 흡광도를 측정하여 정량 하였고 실험 결과를 표 8에 나타내었다. 2) Triglyceride: Triglyceride in blood was measured using a blood triglyceride kit (Wako, Japan) and quantified by measuring absorbance at 410 nm of UV-VIS Spectrophotometer. The experimental results are shown in Table 8.
[표 8]TABLE 8
2. 지질과산화 함량 측정 (TBARS)2. Determination of Lipid Peroxidation Content (TBARS)
4주간 니코틴(Nicotine) 및 실시예로 부터 얻어진 생약추출물을 투여한 후 디에틸 에테르(diethyl ether)로 마취시켜 간을 적출하였다. 적출한 간은 분석할 때까지 -70℃에서 보관하였다. 간 1g을 100mM 삼중염산(Tris-HCl), pH 7.4버퍼로 균질현탁(homogenate) 한 후 TBA 정색시약을 첨가하여 535nm에서 생성된 TBARS 함량을 정량 분석하였고 분석한 결과를 표 9에 나타내었다. TBARS은 티오바부틱 산- 반응 물질(Thiobarbituric Acid - Reactive Substance)이다. After administering nicotine and herbal extracts obtained from Examples for 4 weeks, the liver was extracted by anesthesia with diethyl ether. The extracted liver was stored at -70 ° C until analysis. 1 g of liver was homogenized with 100 mM trichloric acid (Tris-HCl), pH 7.4 buffer, and TBA color reagent was added to quantitatively analyze the TBARS content at 535 nm. The results are shown in Table 9. TBARS is Thiobarbituric Acid-Reactive Substance.
티비에이(TBA) 시약과 반응하는 지질과산화 생성물(MDA-MalonDiAldehyde)을 측정하여 지질 과산화정도 측정하였다.Lipid peroxidation was measured by measuring the lipid peroxidation product (MDA-MalonDiAldehyde) reacting with TBA reagent.
[표 9]TABLE 9
사. 면역력 증가에 대한 시험 four. Test for increased immunity
1. 시험방법 1. Test Method
3주령의 아이시알 쥐(ICR mouse)로부터 적출한 비장을 생리식염수로 세척하여 컴플레이트 알피엠아이(complete RPMI) 1640 메디아(media)에서 비장세포를 분리하였다. 분리된 비장세포를 96웰(well)에 2 x 105 cells/ml로 분주하여 콘 에이(Con A), 엘피에스(LPS) 등의 스티뮬레이터(stimulator)와 함께 배양하면서 각각 다른 농도의 에이치에이티(HAT)를 처리하여 37℃, 5% 이산화탄소 배양기(CO2 incubator)에서 이틀간 배양한 후 알아마 블루(alarmar blue)를 20㎕/well로 처리하여 마이크로 플레이트 리더(micro plate reder)로 흡광도를 측정하였다. Spleens extracted from 3 week old ISR mice were washed with physiological saline to separate splenocytes from complete RPMI 1640 media. The separated splenocytes were dispensed at 96 x wells at 2 x 105 cells / ml and incubated with stimulators such as Con A and LPS to different concentrations of H. After treatment with HAT, the cells were incubated for 2 days at 37 ° C. in a 5% CO 2 incubator and treated with 20 μl / well of alarmar blue to absorb the absorbance with a micro plate reder. Measured.
* 실시예로 부터 얻어진 생약추출물의 농도 : 20, 50, 100, 200 ug/ml * Herbal extract concentrations obtained from the examples: 20, 50, 100, 200 ug / ml
* 모든 실험은 클린벤치에서 하였으며, 메디아(media)를 비롯한 모든 샘플은 여과(22㎛)하여 세포에 처리하였다. * All experiments were performed in a clean bench, and all samples including media were filtered (22 μm) and treated to cells.
* 마이크로 플레이트 리더(micro plate reder): 측정(measurment)은 570㎚와, 레퍼런스(referance) 600㎚에서 측정하였다. Micro plate reder: Measurements were measured at 570 nm and reference 600 nm.
** 알아마 블루의 성분(Alamar Blue assay): 알아마 블루 디(alamar blue dye)는 무독성으로 세포의 활성에 의해 대사 되어 파란색으로 변하는 성질을 이용한 사이토시티(cytotoxity) 측정실험법이고 마이트로 플레이트 리더(micro plate reder)로 측정한 오디(OD)값이 낮을 경우 셀 프로리퍼레션(cell proliferation)이 감소된 값으로 평가한다.Alamar Blue Assay: Alamar Blue Dye is a cytotoxic assay that uses non-toxic metabolism by cell activity to turn blue and is a mitoplate reader. If the OD measured by the micro plate reder is low, the cell proliferation is evaluated to be reduced.
2. 결과2. Results
대조군 에이(Control A)를 자극하여 2일 배양후 알아마 블루(alamar blue)를 투입하였고, 32시간이 경과한 상태에서 실시예로 부터 얻어진 생약추출물의 투입 결과를 표 10에 나타내었다.After stimulating the control A (Control A) was added to the Alama blue (alamar blue) after 2 days of incubation, the results of the injection of the herbal extract obtained from the Example in the state of 32 hours has been shown in Table 10.
[표 10]TABLE 10
아. 흡연 관련 생리 활성에 대한 시험Ah. Tests for Smoking-Related Biological Activities
4주령의 아시알 쥐(ICR mouse)를 1주간 적응시킨 후 실험에 사용 하였다. 동물 사육실은 실온 24± 1℃, 습도 55± 5%, 환기 횟수 12회/시간 및 조명시간 12시간/일(아침 8시 점등, 밤 8시 소등)으로 설정하였다. 실험기간 동안 사료와 물은 자유로이 섭취하게 하였다. Four weeks old asial mice (ICR mice) were used in the experiment after one week of adaptation. The animal breeding room was set at room temperature 24 ± 1 ° C., humidity 55 ± 5%, ventilation number 12 times / hour, and lighting time 12 hours / day (light at 8 am, light at 8 am). Feed and water were taken freely during the experiment.
실시예로 부터 얻어진 생약추출물의 시료는 10시와 17시 하루 2회 경구 투여 하였으며, 시료의 1일 투여량은 매주 쥐의 체중을 측정하여 사람의 1일 섭취량과 사람과 쥐의 평균 대사 체중(체중3/4) 비율로부터 환산 하였고, 사람의 평균체중은 65kg으로 계산하였다. Samples of the herbal extracts obtained from the examples were administered orally twice a day at 10 o'clock and 17 o'clock, and the daily dose of the sample measured the body weight of rats every week to determine the daily intake and The weight was calculated from the ratio of 3/4), and the average human weight was calculated as 65 kg.
1. 니코틴(Nicotine) 배설시험 1. Nicotine excretion test
쥐(Mouse)의 뇨를 수거하기 위하여 메타볼리즘 케이스(metabolism cage)에서 사육 되었다. 14시에 주사용 멸균 증류수에 1mg/ml의 농도로 녹인 니코틴 (nicotine)을 체중 1kg당 10mg 복강 투여 하였다. 다음날 14시에 뇨를 수거하여 가스크로마토그래피(gas chromatography)로 니코틴(nicotine) 농도를 측정 하였다. The urine of mice was bred in a metabolism cage. At 14 o'clock, nicotine dissolved at a concentration of 1 mg / ml in sterile distilled water for injection was intraperitoneally administered 10 mg / kg of body weight. The urine was collected at 14 o'clock the next day and nicotine concentration was measured by gas chromatography.
뇨에 묽은 암모니아수를 가하여 pH 9로 조절 하였다. The pH was adjusted to 9 by adding dilute ammonia water to the urine.
익스트레럿 칼럼(Extrelut column;Merck사 제품)에 15분간 유지시키고 15ml의 에틸아세테이트로 용출하여 용출 에틸아세테이트를 감압하에 증류 제거한 뒤, 잔사에 100㎕의 에틸 아세테이트를 가하여 용해시켜서 분석시료로 하였다. The resultant was maintained for 15 minutes on an Extreme column (manufactured by Merck), eluted with 15 ml of ethyl acetate, and eluted with distillation under reduced pressure. 100 µl of ethyl acetate was added to the residue to dissolve the sample.
가스 크로마토그래피(Gas chromatography;Hewlett Packard 5890, FID)와 2% 써몬(Tharmon) 1000+1% 수산화 칼륨(KOH) 크로모솔브 더블류에이엠(Chromosorb WAM;8/100Mesh)를 충전한 길이 2m, 직경 3mm의 유리 칼럼을 사용하고, 칼럼온도는 100℃, 캐리어 기체는 질소(N2)이고, 유속은 60ml/분으로 수행 하였다. 2m length filled with Gas chromatography (Hewlett Packard 5890, FID) and 2% Tharmon 1000 + 1% Potassium Hydroxide (KOH) Chromosorb WAM (8 / 100Mesh) A 3 mm glass column was used, the column temperature was 100 ° C., the carrier gas was nitrogen (N 2 ), and the flow rate was performed at 60 ml / min.
2. 타(Tar) 해독기능시험 2. Tar detoxification test
주사용 멸균 증류수에 3mg/ml의 농도로 녹인 타(Tar)를 체중 1kg당 30mg 복강 투여하고 7일후의 생존률을 조사하였다. Tar dissolved at a concentration of 3 mg / ml in sterile distilled water for injection was intraperitoneally administered 30 mg per kg of body weight and the survival rate after 7 days was examined.
3. 혈장 총산화력 시험3. Plasma Total Oxidation Test
실시예로 부터 얻어진 생약추출물을 3주간 경구투여한 후 쥐(mouse)를 에테르(ether)로 마취 시키고 심장에서 혈액을 채취하여 항응고제가 포함되어있는 시험관에서 혈장을 분리하였다. 혈장 총산화력은 랜독스(Randox사;U.K.)의 총 산화력(Total antioxidant status )측정용 키트(Kit)를 이용하여 측정하였다. After oral administration of the herbal extracts obtained from the examples for 3 weeks, mice were anesthetized with ether and blood was collected from the heart to separate plasma from test tubes containing anticoagulants. Plasma total oxidative power was measured using a kit for measuring total antioxidant status of Randox (U.K.).
4. 통계처리 4. Statistical Processing
측정치는 학생의 티-테스트(Student's t-test)으로 분석 되었으며 엠±에스이엠(M± SEM)으로 표시 하였다. The measurements were analyzed by student's t-test and expressed in M ± SEM.
5. 결과 및 고찰 5. Results and Discussion
① 니코틴(Nicotine) 배설시험 결과 ① Nicotine excretion test results
흡연을 중단하면 신체에 축척된 니코틴이 감소하기 시작한다. 이 기간 동안 니코틴에 중독 되어 있는 신체의 니코틴에 대한 욕구를 참기가 매우 어렵다. 금연에 성공하기 위하여 빠른 시간에 체내에 축척된 니코틴을 제거하는 게 매우 중요하다. 이는 모든 중독성 증상에 공통적으로 적용된다고 알려져 있다. If you stop smoking, the nicotine accumulated in your body begins to decrease. During this period, it is very difficult to tolerate the body's desire for nicotine, which is addicted to nicotine. It is very important to get rid of nicotine accumulated in your body quickly in order to succeed in quitting smoking. It is known to be common to all addictive symptoms.
표 11는 실시예로 부터 얻어진 생약추출물의 섭취가 니코틴의 소변 배설에 미치는 영향을 아이씨알 쥐(ICR mouse)에서 조사 한 것이다. Table 11 examines the effect of ingestion of herbal extracts obtained from Examples on urinary excretion of nicotine in ICR mice.
[표 11] TABLE 11
(1Values are mean± SEM ), n=6. ( 1 Values are mean ± SEM), n = 6.
*P<0.05 for the comparison with control group. * P <0.05 for the comparison with control group.
실시예로 부터 얻어진 생약추출물의 섭취군에서 소변을 통한 니코틴 배설이 대조군에 비하여 17.3배 증가 하였다. The urine nicotine excretion was increased by 17.3 times in the intake group of the herbal extract obtained from the example compared to the control group.
② 타(Tar) 해독기능시험 결과 ② Result of Tar detoxification function test
표 12는 실시예로 부터 얻어진 생약추출물의 섭취가 타(Tar)의 독성에 미치는 영향을 아이시알 쥐(ICR mouse)에서 조사한 것이다. Table 12 examines the effects of intake of herbal extracts obtained from the examples on the toxicity of Tar in ISR mice.
[표 12]TABLE 12
1n=10. 1 n = 10.
대조군에서는 타(tar) 중독된 10마리의 쥐 중 1마리가 생존한 반면 실시예로부터 얻어진 생약추출물을 투여한 투여군에서는 7마리가 생존하여 실시예로부터 얻어진 생약추출물이 타(tar)중독에 의한 쥐의 사망률을 현저하게 감소 시켰다. 이상의 결과는 실시예로부터 얻어진 생약추출물이 효과적으로 니코틴을 배설 시키고 타(tar)의 독성을 감소시킴을 보여 주고 있다. 따라서 실시예로 부터 얻어진 생약추출물은 흡연으로 인하여 체내에 축척된 니코틴 및 타(tar)와 같은 기타 독성의 물질의 제거에 관련된 신진대사와 생리활성을 높이는 작용을 한다고 추측된다. In the control group, one out of ten tar-addicted rats survived, whereas in the administration group to which the herbal extract obtained from the Example was administered, seven survived, and the herbal extract obtained from the Example was treated by tar poisoning. Significantly reduced mortality. The above results show that the herbal extracts obtained from the examples effectively excrete nicotine and reduce the toxicity of tar. Therefore, the herbal extracts obtained from the examples are supposed to act to enhance metabolism and physiological activity related to the removal of other toxic substances such as nicotine and tar accumulated in the body due to smoking.
산소는 유기호홉을 하는 생물에게 필수적인 원소이지만 에너지 대사 과정중 불완전연소과정에서 발생하는 활성산소는 세포내의 거대분자를 변성, 파괴하여 세포의 항상성을 깨트려 세포를 사멸 시킨다. Oxygen is an essential element for organisms doing organic hops, but active oxygen generated during incomplete combustion during energy metabolism destroys and destroys homeostasis of cells by denaturing and destroying macromolecules in cells.
활성 산소는 담배, 매연 등의 요인에 의해 생성되어 단백질, 디엔에이(DNA), 효소, 티셀(T-cell)등의 생체 구성요소를 손상시켜 각종 질환을 일으키며, 특히 생체막의 구성성분인 불포화 지방산을 공격하여 과산화지질을 생성하여 노화 및 성인병을 일으킨다고 알려져 있다.Active oxygen is generated by factors such as tobacco and soot, and damages biological components such as proteins, DNA, enzymes, and T-cells to cause various diseases. Especially, unsaturated fatty acids, which are components of biological membranes, It is known to attack and produce lipid peroxide, causing aging and adult disease.
③ 혈장 총산화력 시험 결과 ③ Plasma total oxidation test result
실시예로 부터 얻는 생약추출물을 투여한 동물로부터 혈장을 분리 하여 총산 화력(total antioxidant status)을 측정한 결과를 표 13에 나타 내었다. 표 13은 3주 동안 기능성 음식을 처리한 쥐와 일반쥐의 전체적인 혈장의 총산화력 비교한 것이다.Table 13 shows the results of measuring total antioxidant status by separating plasma from the animals administered with the herbal extracts obtained from the examples. Table 13 compares the total oxidative powers of plasma in rats treated with functional foods for three weeks.
실시예로 부터 얻는 생약추출물을 투여한 투여군의 총산화력이 대조군에 비하여 38.8% 증가 하였으며 유의차가 있었다.(P<0.05) 혈장의 항산화력은 체내 항산화력을 대표하는 값으로 생각될 수 있으며, 혈장의 총산화력 증가는 실시예로 부터 얻는 생약추출물 투여에 의해 체내 항산화력이 증가하였음을 의미한다. The total oxidative power of the group administered with the herbal extract obtained from the Example increased by 38.8% compared to the control group and there was a significant difference. (P <0.05) The antioxidant power of plasma may be considered as a representative value of the antioxidant power in the body, and the plasma Increasing the total oxidative power of means that the antioxidant power in the body was increased by administration of the herbal extract obtained from the example.
카테친(Catechine)과 같은 폴리페놀(Polyphenol)류의 항산화제가 함유된 녹차도 혈장 항산화력을 증가 시킨다고 보고되고 있다. 이러한 결과는 실시예로 부터 얻는 생약추출물을이 생체 항산화력을 증가시켜서 흡연 등 요인에 의한 산화적 손상에 의해 발생하는 질병으로부터 생체를 보호하는 생약추출물을 첨가대상체로 사용될 수 있음을 보여 주고 있다. Green tea containing antioxidants of polyphenols such as catechin has also been reported to increase plasma antioxidant activity. These results show that the herbal extract obtained from the example can be used as an additive to increase the biological antioxidant power of the herbal extract that protects the living body from diseases caused by oxidative damage caused by factors such as smoking.
[표 13] TABLE 13
(1Values are mean± SEM), n=8. ( 1 Values are mean ± SEM), n = 8.
(2Water-soluble vitamin E analogue) ( 2 Water-soluble vitamin E analogue)
*P<0.05 for the comparison with control group.* P <0.05 for the comparison with control group.
상술한 실험결과로부터 본 발명의 생약추출물을 인체에 투여함과 동시에 니코틴을 투여할 경우 혈액중의 니코틴 양을 저하시키는 작용과 뇨중의 니코틴을 배출시키는 작용을 나타낸다. 또한 일산화탄소에 폭로시킬 경우 혈액중의 CO-헤모글로빈 농도를 저하시키는 작용을 나타낸다. 또한 높은 항산화력 및 총콜레스테롤, 혈중지방, 지질과산화에 효과를 나타내므로 인체의 면역력을 증가시키고 질병에 대한 면역력을 높일 수 있는 이점이 있다. From the above experimental results, when the herbal extract of the present invention is administered to the human body and at the same time nicotine is administered, the effect of lowering the amount of nicotine in the blood and the release of nicotine in the urine is shown. In addition, exposure to carbon monoxide has the effect of lowering the concentration of CO-hemoglobin in the blood. In addition, high antioxidant power and total cholesterol, blood fat, lipid peroxidation effect is shown to increase the body's immunity and has the advantage to increase the immune system against disease.
본 발명의 생약추출물은 혈액중의 니코틴을 포함하여 흡연으로 인하여 발생할 수 있는 인체내의 유해성분을 제거함으로써 흡연으로 인하여 발생할 수 있는 각종 질병에 대한 예방 효과를 기대할 수 있다. The herbal extract of the present invention can be expected to have a preventive effect against various diseases that may occur due to smoking by removing the harmful components in the human body that may occur due to smoking, including nicotine in the blood.
또한 본 발명의 생약추출물은 기능성 식품에 첨가하여 간편하게 복용할 수 있을 뿐만 아니라 다양한 형태의 제제로 제조하여 공급할 수 있는 이점을 제공한다.In addition, the herbal extract of the present invention provides an advantage that can be easily added to the functional food to be prepared and supplied in various forms of preparation.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040082405A KR100761552B1 (en) | 2004-10-15 | 2004-10-15 | Herbextract for removing harmful elements caused by smoking and manufacturing method of the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040082405A KR100761552B1 (en) | 2004-10-15 | 2004-10-15 | Herbextract for removing harmful elements caused by smoking and manufacturing method of the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060033345A true KR20060033345A (en) | 2006-04-19 |
KR100761552B1 KR100761552B1 (en) | 2007-10-04 |
Family
ID=37142479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040082405A KR100761552B1 (en) | 2004-10-15 | 2004-10-15 | Herbextract for removing harmful elements caused by smoking and manufacturing method of the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100761552B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100812968B1 (en) * | 2006-12-11 | 2008-03-11 | 조진원 | A study of purifying hunman inner body with natural herbal plants |
US20130337089A1 (en) * | 2011-03-10 | 2013-12-19 | University-Industry Cooperation Group Of Kyung Hee University | Composition for preventing or treating hearing loss |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101470603B1 (en) * | 2013-10-17 | 2014-12-10 | 홍성창 | Manufacturing method of herbextract for removing harmful elements caused by smoking |
KR20160144627A (en) | 2015-06-09 | 2016-12-19 | (주)메디언스 | Composition for detoxification of human body |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100581216B1 (en) * | 1998-12-31 | 2006-08-18 | 주식회사 태평양 | Blended tea effective to eliminate nocotine with excellent preference |
KR100406158B1 (en) * | 2001-03-06 | 2003-11-15 | 조진원 | The human body a poisonous toxic substance eliminate waste matter from the system natural product a manufacturing process |
KR20030087728A (en) * | 2002-05-09 | 2003-11-15 | 주식회사 남양알로에 | Composition for detoxifying toxic substances having Aloe vera gel and propolis |
KR20020065434A (en) * | 2002-07-06 | 2002-08-13 | 임병윤 | chewing gum contains of green tea leaf powder or fermentation tea leaf powder |
KR100553576B1 (en) * | 2004-03-29 | 2006-02-22 | 김찬호 | Functional healthy cadence good stuffs and manufacturing method thereof |
-
2004
- 2004-10-15 KR KR1020040082405A patent/KR100761552B1/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100812968B1 (en) * | 2006-12-11 | 2008-03-11 | 조진원 | A study of purifying hunman inner body with natural herbal plants |
US20130337089A1 (en) * | 2011-03-10 | 2013-12-19 | University-Industry Cooperation Group Of Kyung Hee University | Composition for preventing or treating hearing loss |
US9694043B2 (en) | 2011-03-10 | 2017-07-04 | University-Industry Cooperation Group Of Kyung Hee University | Composition for preventing or treating hearing loss |
Also Published As
Publication number | Publication date |
---|---|
KR100761552B1 (en) | 2007-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Panda | Handbook on medicinal herbs with uses: medicinal plant farming, most profitable medicinal plants in India, medicinal plants farming in India, plants used in herbalism, medicinal herbs you can grow, medicinal herbs and their uses, medicinal herbs, herbal & medicinal plants, growing medicinal herb, most profitable medicinal herbs growing with small investment, herbal medicine herbs | |
KR100793204B1 (en) | Pharmaceutical Composition for Treating or Preventing Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient | |
Qasem | Prospects of wild medicinal and industrial plants of saline habitats in the Jordan valley | |
KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
KR100968109B1 (en) | Calcium?compound containing natural product composition for curing a hangover and preparation method thereof | |
Li et al. | 1. GINSENG | |
KR20100042337A (en) | The composition of traditional oriental medicines for reheumatoid arthritis and the method of preparing medicine for it | |
CN103168883A (en) | Pathogenic microorganism preventing antiviral tea beverage granules capable of boosting immunity and preparation method thereof | |
Middleditch | Kuwaiti Plants: Distribution, Traditional Medicine, Pytochemistry, Pharmacology and Economic Value | |
Hutchens | A Handbook of Native American Herbs: The Pocket Guide to 125 Medicinal Plants and Their Uses | |
Khursheed et al. | Phytochemical and pharmacological investigations on Adhatoda zeylanica (medic.): A review | |
KR100823978B1 (en) | Herb extract for removing harmful elements accumulated in a human body and manufacturing method of the same | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
CN108174945B (en) | Throat clearing food for smokers and preparation method thereof | |
CN104306659B (en) | A kind of Chinese medicine composition for treating diabetes B | |
KR100406158B1 (en) | The human body a poisonous toxic substance eliminate waste matter from the system natural product a manufacturing process | |
KR101195109B1 (en) | composition of health food | |
WO2002066041A1 (en) | Natural composition | |
KR101470603B1 (en) | Manufacturing method of herbextract for removing harmful elements caused by smoking | |
KR100761552B1 (en) | Herbextract for removing harmful elements caused by smoking and manufacturing method of the same | |
KR101987554B1 (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
KR20130029284A (en) | Composition of healthy foods for treatment of dementia | |
KR100812968B1 (en) | A study of purifying hunman inner body with natural herbal plants | |
KR100566901B1 (en) | Ice Cream to which Herb Extracts is added and the manufacturing method thereof | |
KR101093730B1 (en) | Smilax china extracts compositions for treating or preventing inflammatory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20111018 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |